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Abstract
Glycogen is a branched polymer of glucose that acts as a store of energy in times of nutritional 
sufficiency for utilization in times of need. Its metabolism has been the subject of extensive 
investigation and much is known about its regulation by hormones such as insulin, glucagon and 
adrenaline (epinephrine). There has been debate over the relative importance of allosteric 
compared with covalent control of the key biosynthetic enzyme, glycogen synthase, as well as the 
relative importance of glucose entry into cells compared with glycogen synthase regulation in 
determining glycogen accumulation. Significant new developments in eukaryotic glycogen 
metabolism over the last decade or so include: (i) three-dimensional structures of the biosynthetic 
enzymes glycogenin and glycogen synthase, with associated implications for mechanism and 
control; (ii) analyses of several genetically engineered mice with altered glycogen metabolism that 
shed light on the mechanism of control; (iii) greater appreciation of the spatial aspects of glycogen 
metabolism, including more focus on the lysosomal degradation of glycogen; and (iv) glycogen 
phosphorylation and advances in the study of Lafora disease, which is emerging as a glycogen 
storage disease.
 INTRODUCTION
Glycogen is a branched polymer of glucose that serves as an osmotically neutral means to 
store glucose in cells in times of nutritional plenty for utilization in times of need [1]. It is 
present in organisms from bacteria and archaea to humans. Plants synthesize related glucose 
polymers in the form of starch which is composed of amylopectin, a polysaccharide 
chemically similar to glycogen, and amylose, which is an essentially unbranched linear 
polymer of glucose [2,3]. Therefore polymerization of glucose may be a universal 
mechanism for energy storage in Nature.
The discovery of liver glycogen in 1857 is attributed to Claude Bernard (reviewed in [4]). A 
century and a half later, several of his original tenets are still accepted and study of glycogen 
metabolism in the second half of the 20th Century introduced a series of novel biochemical 
concepts, now engrained in current thinking about biological regulation, and resulted 
directly in the award of four Nobel Prizes (Carl and Gerty Cori in 1947, Louis Leloir in 
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1970, Earl Sutherland in 1971, and Edwin Krebs and Edmond Fischer in 1992; see http://
nobelprize.org/nobel_prizes/). Among the scientific advances intertwined with 20th Century 
research on glycogen are the discovery of NDP-sugars as intermediates in polysaccharide 
synthesis, reversible protein phosphorylation, the first protein kinases and protein 
phosphatases, the role of allosteric control of enzymes by ligands, hormonal controls of 
intracellular enzymes by insulin, and hormonal control by cAMP produced via activation of 
G-protein-coupled hormone receptors.
The present review does not attempt to be comprehensive, rather it highlights certain major 
themes and areas of recent progress on eukaryotic glycogen metabolism. The focus is on 
muscle rather than liver and on synthesis rather than degradation via the phosphorylase 
pathway. The reader is referred to earlier reviews for additional background [1,5–20]. 
Wilson et al. [21] provide a recent review of glycogen metabolism in bacteria and yeast. 
Literature coverage is roughly until July 2011.
 GLYCOGEN STRUCTURE
The primary polymerization in glycogen is provided by α-1,4-glycosidic linkages between 
glucose residues; branchpoints are introduced by α-1,6-glycosidic linkages (Figure 1). 
Glycogen isolated from biological sources is polydisperse, existing as a population of 
molecules of different sizes. In addition, branchpoints are not in precisely defined locations, 
so that molecules of identical mass need not have identical chemical structures. Therefore 
precise three-dimensional structures of glycogen cannot be determined by the classical 
approaches of structural biology. The best that can be done to analyse the chemistry of 
glycogen molecules is to define molecular mass distributions, average chain lengths and 
average branching frequencies. Nonetheless, important insights into glycogen structure have 
emerged. A well-accepted model for glycogen structure [22–25] categorizes the chains as 
inner B-chains, which would normally contain two branchpoints, and outer A-chains, which 
are unbranched (Figure 1). Chemical analysis of mammalian glycogen suggests that the 
average chain length is ~13 residues [23,24]. In this model, glycogen would consist of a 
series of tiers. An important feature is that the outermost tier of any molecule completely 
formed in this way would contain 50% of the total glucose residues of the molecule as 
unbranched A-chains (Table 1). Note, however, that only a fraction of these outer-chain 
glucose residues are accessible to the degradative enzyme glycogen phosphorylase, which 
stalls four residues from a branch without the intervention of the debranching enzyme [AGL 
(amylo-α-1,6-glucosidase, 4-α-glucanotransferase)]. It is sometimes noted that branchpoints 
in glycogen occur every ~12 residues, in apparent contradiction of the idea of B-chains 
containing two branches per 13 residues. However, if half of the glycogen molecule is 
composed of unbranched outer A-chains, then the 1 in 12 average number is consistent. It 
has been calculated that addition of a 13th tier to a glycogen molecule would add an 
impossible density of glucose residues, making 12 tiers a theoretical maximum [25]. 
Therefore a full-size glycogen molecule in this model would consist of 12 tiers, for a total of 
~55000 glucose residues, a molecular mass of ~107 kDa and a diameter of ~44 nm. In fact, 
careful analysis of the sizes of glycogen particles present in skeletal muscle by electron 
microscopy has indicated that few full-size glycogen particles exist and the average diameter 
is closer to 25 nm or seven tiers [15]. The model described above (Figure 1B) of necessity is 
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highly stylized, and the actual lengths of the chains, especially the outer chains, would have 
a major impact on the overall structure and average branching statistics of the population. 
Indeed, the stochastic nature of glycogen synthesis and the randomness of its metabolism 
could well mean that individual glycogen molecules deviate significantly from these 
theoretical formulations, and could be a lot less symmetrical than in the model, with not all 
tiers being intact for example. Some more detailed structural information has been obtained 
with simpler oligosaccharides. Polymeric glucose forms helical structures [25]. In 
amylopectin, parallel helices are thought to form semi-crystalline regions, excluding water 
and making the polysaccharide quite insoluble. In line with this idea, a crystal structure has 
been obtained for a 26-residue cyclodextran [26]. In this constrained structure, two 
antiparallel 13-residue helices are formed, and each is stabilized by a network of intrahelical 
hydrogen bonds; it is likely that some features of these structures are relevant to those of 
both natural amylopectin and glycogen.
Individual glycogen molecules are too small to be detected by normal light microscopy. 
Histochemical staining for glycogen in cells or tissues can therefore only reveal 
conglomerates of glycogen particles. However, glycogen molecules are large enough to be 
detected by electron microscopy and have been described as rosette-like β-particles in 
muscle and larger α-particles in liver [27]. The β-particles would appear to correspond to the 
type of structures just described. The α-particles seen in liver appear to be formed of 
aggregates of β-particles, although the chemical basis for the aggregation is not well 
understood [28,29]. Analysis of gently purified liver glycogen by size-exclusion 
chromatography techniques suggests a covalent linkage [29]. This conclusion is also 
supported by stochastic modelling of the assembly of such large glycogen structures [30]. 
One possibility would be the presence of infrequent extended polyglucose chains, as is seen 
in amylopectin [2,3]. However, this is an area that clearly deserves further exploration.
Although predominantly composed of glucose residues, glycogen contains other trace 
constituents, notably glucosamine [31,32] and phosphate. The most studied of these is 
covalent phosphate. For many years, phosphate in glycogen was thought to be no more than 
a minor contaminant and the amount of phosphate in purified glycogen was thought to 
correlate with purity. Not until the early 1980s was the first convincing report that this 
‘minor contaminant’ was an integral part of the polymer [33]. Whelan and colleagues also 
documented the presence of phosphate in glycogen and postulated that it existed as a C6-
monoester, thereby blocking a potential branchpoint, and as a C1–C6 bridging 
phosphodiester, representing an alternative branchpoint [34,35]. Recent analyses indicate a 
frequency of glycogen phosphorylation of one phosphate per ~650 glucoses in rabbit 
skeletal muscle and one per ~1500 residues in mouse muscle glycogen [36,37]. From 
analysis of phospho-oligosaccharides purified from digested rabbit muscle glycogen, the 
phosphate has been determined by MS and NMR to exist as C2- and C3-phosphomonoesters, 
probably introduced as side reactions during the action of the normal synthetic enzyme, 
glycogen synthase [38] (see below). No evidence was found for the presence of C6-
phosphoesters. Excessive phosphorylation of glycogen is associated with a form of epilepsy, 
called Lafora disease [39–41] (see below). A glycogen molecule undergoes multiple cycles 
of expansion and contraction. Thus chemical and metabolic insults throughout its lifetime 
may accumulate and result in an aberrant structure that sometimes escapes normal 
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metabolism and degenerates into an insoluble deposit, much as other insoluble cellular 
structures form in various neurological disorders. Whelan and colleagues had proposed 
exactly this scenario, that the chemical modifications in glycogen might mark the age of the 
molecule and target the need for its disposal [34]. In fact, in normal aging tissues, even in 
the absence of overt disease, glycogen-like deposits distinct from normal glycogen have 
been described in brain, as corpora amylacea [42], and in heart as basophilic degeneration or 
cardiac colloid [43].
Glycogen forms higher-order assemblages with associated proteins [9,15,18,44,45]. Fischer 
and colleagues were the first to partially purify from muscle what they termed ‘glycogen 
particles’ which contained glycogen, several proteins and elements of sarcoplasmic 
reticulum [46–48]. The particles result from the ability of associating proteins to bind to 
glycogen, sometimes also to each other and to membranes (Figure 2). Known glycogen-
associated proteins are the initiator glycogenin, the metabolic enzymes glycogen synthase, 
glycogen phosphorylase and the debranching enzyme AGL, and several regulatory proteins 
including phosphorylase kinase and members of the PP (protein phosphatase) 1G family. In 
addition, the β-subunit of AMPK (AMP-activated protein kinase) has a CBM20 
(carbohydrate-binding module 20) domain [49,50] and has been shown to bind glycogen 
[51,52]. More recently identified glycogen-associated proteins are laforin [53,54] and Stbd1 
(starch-binding domain protein 1)/genethonin 1 [55]. Laforin and Stbd1 also bind to 
glycogen via a CBM20 domain. A recent proteomics study of gently purified liver glycogen 
[45] identified most of the above proteins, except phosphorylase kinase and AMPK, as well 
as some other surprising ones, including ferritin light and heavy chains. Such novel 
candidates for glycogen binding, of course, require further validation, but virtually all bona 
fide glycogen-associating proteins, until now, have been shown to have a functional role in 
glycogen metabolism. Notably absent from the list is the branching enzyme, which can 
obviously interact with glycogen, but which does not appear to form a stable association 
[56]. The glycogen particle is unlikely to be a complex with a rigorous stoichiometry as is 
observed, for example, in ribosomes or the pyruvate dehydrogenase complex. Furthermore, 
there is a strong likelihood of compositional differences between and even within cell types, 
for example, skeletal muscle where glycogen particles are found in different subcellular 
locations [57]. Neither can we exclude alterations in composition controlled by 
physiological conditions.
High-molecular-mass glycogen is insoluble in ethanol, a property frequently used for its 
purification. In contrast, treatment of cell extracts with TCA (trichloroacetic acid) 
precipitates protein, but leaves high-molecular-mass glycogen in solution. A portion of the 
glycogen, however, is precipitated by TCA and has been termed ‘proglycogen’. Lomako et 
al. [58–60] suggested that proglycogen was a distinct molecular and metabolic entity, 
possibly with its own metabolic pathways. The matter has been somewhat controversial 
[10,61–63], and no distinct proglycogen synthase has been identified at the molecular level. 
A strong argument against the existence of a genetically separate proglycogen synthase 
comes from the fact that a mouse with the muscle glycogen synthase gene disrupted has 
undetectable muscle glycogen levels [64]. Also, evidence from a cell model [61] and from 
analyses of muscles [57] suggested instead a continuum of glycogen species of different 
sizes with no discrete lower-molecular-mass form. This is not to say that smaller 
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(proglycogen) particles might not behave differently than larger molecules and some studies 
make this argument [65]. Unquestioned is the operational definition of proglycogen, 
reflecting the fact that smaller glycogen particles contain a sufficient proportion of protein to 
make them TCA-insoluble.
 OVERVIEW OF GLYCOGEN METABOLIC PATHWAYS
In mammals, the major deposits of glucose are in skeletal muscle and liver, although many 
other tissues are capable of glycogen synthesis, including kidney, heart, fat and brain. The 
precursors for glycogen synthesis are either glucose, derived from newly ingested 
carbohydrate, or gluconeogenic precursors, such as lactate or alanine, a process sometimes 
termed ‘glyconeogenesis’ or the ‘indirect pathway’ [66]. The latter pathway is carefully 
reviewed by Agius [17]. The direct pathway requires transport of glucose into cells, by one 
or more of several GLUTs (glucose transporters) [67]: GLUT1 is widely distributed and 
provides basal glucose transport; GLUT4 is up-regulated by insulin and is important in 
insulin-sensitive tissues such as skeletal muscle and adipose tissue; and GLUT2 is prominent 
in liver and the β-cells of the pancreas and admits glucose based on a positive glucose 
gradient between the blood and the tissue.
The immediate glucose donor for glycogen synthesis is the activated NDP-sugar UDP-
glucose, which is produced by UDP-glucose pyrophosphorylase at the expense of converting 
UTP into UDP [12] (Figure 3). There is a specialized initiation step whereby glycogenin 
[68–71] self-glucosylates to form an oligosaccharide primer chain. Via its extreme C-
terminus, glycogenin can interact directly with glycogen synthase which is responsible for 
the formation of the large majority of the α-1,4-glycosidic linkages of glycogen, also 
utilizing UDP-glucose as the glucosyl donor. The α-1,6-glycosidic branchpoints are formed 
by the action of the branching enzyme. Yagi et al. [72] described a Nudix hydrolyase that 
they proposed was relatively specific for UDP-glucose. This UGPPase (UDP-glucose 
pyrophosphatase), encoded by the NUDT14 gene, is widely distributed in mammalian 
tissues and has the potential to modulate glycogen synthesis by setting the level of the 
glucosyl donor UDP-glucose, even if this would be energetically costly [73]. Whether 
UGPPase has a physiological role in glycogen metabolism remains an open question. 
Glycogen is degraded by two distinct pathways. In the first, retrieval of glucose, in muscle to 
fuel contraction or in liver to provide glucose for export to the bloodstream, is mediated by 
the actions of glycogen phosphorylase and the debranching enzyme AGL. The immediate 
products of glycogenolysis are glucose 1-phosphate from α-1,4-linkages and free glucose 
from α-1,6-linkages. A primary stimulus for hepatic glycogenolysis is nutritional 
deprivation, with corresponding elevation of counterregulatory hormones such as glucagon 
[11]. Breakdown of muscle glycogen accompanies exercise, under conditions of increased 
cAMP and Ca2+ [11]. In the second pathway for degradation, glycogen is transferred to the 
lysosome and hydrolysed to glucose by the lysosomal α-glucosidase [also known as GAA 
(acid α-glucosidase), acid maltase] [74].
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 GLYCOGEN SYNTHESIS
 Glycogenin
Glycogenin is a self-glucosylating protein that transfers glucose from UDP-glucose first to a 
tyrosine residue within the protein itself and then forms α-1,4-glycosidic linkages until the 
oligosaccharide chain is extended to a length of 10–20 residues [75–78]. It is a member of 
the family 8 retaining glycosyltransferases [79,80]. Humans have two genes that encode 
glycogenin: GYG1, which is more widely expressed, and GYG2, whose expression is 
restricted to liver, heart and pancreas [81]. Rodents, on the other hand, have a single 
glycogenin gene. There is a report [82] of a patient with mutations in GYG1, a nonsense 
mutation in one allele and a missense mutation, T83M, in the other allele, leading to inactive 
glycogenin-1. The patient had muscle weakness and had presented with cardiac 
abnormalities following a bout of exercise. The patient’s skeletal muscle completely lacked 
glycogen, but abnormal PAS (periodic acid–Schiff) staining structures, indicative of 
polysaccharide, were seen in cardiomyocytes, possibly resulting from expression of the 
GYG2 gene.
Structurally, glycogenin is a member of the A-type glycosyltransferase family which is 
characterized by a single Rossmann-fold domain with additional elaborations of secondary 
structure that control both donor nucleotide sugar specificity and acceptor specificity [83] 
(Figure 4A). UDP-glucose is bound in a metal-dependent fashion at the C-terminal ends of 
the central β-sheet structure (Figure 4B). The metal ion, most likely Mn2+, is co-ordinated 
by two aspartate residues in the canonical DXD motif, a histidine residue from the protein 
and two phosphate oxygen atoms contributed by the pyrophosphate group of UDP. The 
primary function of the metal ion is to stabilize the UDP leaving group during glucosyl 
transfer. Glycogenin is an example of a retaining glycosyltransferase, in that the α-
configuration of the C1-anomeric carbon is retained in the product. The chemical mechanism 
of glucosyl transfer in retaining glycosyltransferases generates considerable debate. The 
simplest explanation for retention of stereochemistry is through the use of a SN2 double-
displacement mechanism and an enzyme-bound intermediate with inverted stereochemistry. 
However, the identification of an enzyme active-site nucleophile with sufficient catalytic 
impact has proved elusive, although Asp159 and Asp162 seem to play important roles in 
glycogenin [84]. More recently, there has been some speculation that this class of enzyme 
achieves retention of configuration by means of an SNi-type mechanism where the 
nucleotide diphosphate serves as the general base to activate the acceptor hydroxy group 
[85]. The acceptor for glucose transfer by glycogenin is itself, either Tyr195 in the initial 
phase of the reaction or the terminal glucose residue of the growing chain subsequently 
[84,86,87].
The different chemistries of these reactions dictate that there are two phases to the overall 
process, for two reasons. First, activation of the initial tyrosine hydroxy group and the 
subsequent 4′-hydroxy groups of glucose as nucleophiles are not energetically equivalent. 
Secondly, Tyr195 in the unglucosylated protein is too far away from an active site to permit 
an intramolecular reaction. The simplest explanation of the available data is that the initial 
transfer of glucose from UDP-glucose to Tyr195 occurs through an intermolecular reaction 
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that switches to an intramolecular reaction as the chain length increases [87]. The initial 
stages of the glycosyl-transfer reaction appear to follow a processive reaction mechanism 
where the mono-, di-, tri- and penta-glucosylated species do not accumulate to any 
significant extent [87]. However, there are slow steps associated with the generation of the 
tetra- and hexa-glucosylated forms [87]. Subsequent products are more distributive in nature, 
with all species between seven and sixteen forming a normal distribution. In this manner, 
glycogenin generates the primer for bulk glycogen synthesis by glycogen synthase.
The association between glycogenin and glycogen synthase is mediated by two mechanisms: 
(i) association of the glucosyl-primer chain with the active site of glycogen synthase during 
catalysis; and (ii) protein-mediated association, minimally through a conserved amino acid 
sequence in the C-terminal domain of glycogenin [88]. The C-terminal 33 amino acids of 
glycogenin are sufficient for purification of glycogen synthase from tissue extracts and this 
interaction may be mediated by the relatively conserved sequence motif (WEX2–4DYL/M). 
However, the data suggest that other sites of association may also exist [88].
 Glycogen synthase
In eukaryotes, glycogen synthase is responsible for the bulk synthesis of glycogen by 
formation of the α-1,4-glycosidic linkages with UDP-glucose as the glucosyl donor. Note 
that glycogen synthesis in bacteria and starch synthesis in plants utilize ADP-glucose [1]. 
Eukaryotic glycogen synthase is allosterically activated by glucose 6-phosphate and 
negatively regulated by covalent phosphorylation. The presence of glucose 6-phosphate 
overcomes inactivation due to phosphorylation and can restore full activity. This property led 
to the use of assays of the enzyme in the presence or absence of glucose 6-phosphate to give 
the ratio of activity with and without glucose 6-phosphate as a surrogate measure of 
phosphorylation state (see [89]) even though not all phosphorylation sites affect activity. 
Various modifications of the assay have been used to increase sensitivity to changes in 
phosphorylation of inactivating sites, such as measuring at low and high glucose 6-
phosphate concentrations or altering the UDP-glucose concentration (see, for example, 
[90]). In the literature, reference to the activity or activation state of glycogen synthase is 
normally to some version of this assay and, when the enzyme source is a cell or tissue 
extract, it is taken as an indicator of phosphorylation in vivo. It must be recalled that, in the 
cell, the momentary activity of a glycogen synthase molecule is minimally a function of the 
concentrations of UDP-glucose, glucose 6-phosphate and glycogen, and its phosphorylation 
state, of which only phosphorylation is reflected in these standard assays. Measured activity 
and inferred in vivo activity need to be distinguished, although we are all sometimes careless 
in our usage.
Mammals have two genes that encode glycogen synthase: GYS1, which is expressed in 
skeletal muscle and most other cells capable of glycogen synthesis, and GYS2, which 
appears to be restricted to liver [91,92]. The yeast Saccharomyces cerevisiae also has two 
genes for this enzyme, GSY1 and GSY2, with Gsy2p normally the predominant isoform 
[93]. Mammalian glycogen synthase was one of the first examples of a multiply 
phosphorylated enzyme [94] and efforts to identify the responsible protein kinases by 
several groups in the late 1970s and 1980s contributed significantly to protein kinase 
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discovery in the days before cDNA cloning. A number of protein kinases were linked to the 
in vitro phosphorylation of subsets of the nine sites of muscle glycogen synthase (Figure 5 
and Table 2). The sites are located at the N- and C-termini of the protein. From Ser→Ala 
mutagenesis, four of the sites, 2, 2a, 3a and 3b, were identified as the most important in 
determining enzyme activity of rabbit muscle enzyme [95,96]. Similar analysis of liver 
glycogen synthase, however, suggested a dominant role for phosphorylation of site 2 [97]. 
The yeast glycogen synthases lack the N-terminal phosphorylation and have three C-
terminal sites: Ser650 and Ser654, that resemble mammalian sites 3a and 3b, and Thr667 
which is unique to yeast [98]. Phosphorylation of Thr667 by the cyclin-dependent kinase 
Pho85p appears to dominate inactivation ([99], and W.A. Wilson and P.J. Roach, 
unpublished work). Work on glycogen synthase phosphorylation also led to the concept of 
hierarchal phosphorylation [100,101], whereby the introduction of one phosphate enables 
the addition of a second. The prototype for this mechanism was the requirement of prior 
phosphorylation of glycogen synthase by protein kinase CK2 in order that GSK3 (glycogen 
synthase kinase 3) could add four successive phosphates per subunit [102] (Figure 5). The 
molecular basis for the phenomenon is that GSK3 recognizes the sequence -SXXXpS- in 
glycogen synthase [103], a conclusion that was supported by solution of the three-
dimensional structure of GSK3 [104,105]. There are two isoforms, GSK3α and GSK3β 
[106]. In relation to glycogen metabolism, GSK3α appears to be more important in liver 
[107] and GSK3β appears to be more important in muscle [108]. Both GSK3 isoforms are 
inactivated by phosphorylation of an N-terminal regulatory site by Akt/PKB (protein kinase 
B) [109]. A second example of hierarchal phosphorylation was provided by the observation 
that protein kinase CK1 (casein kinase 1) preferred sites with the motif -pSXXS- in 
glycogen synthase [110]. A second covalent modification of glycogen synthase has been 
proposed, namely O-linked attachment of N-acetylglucosamine, with the suggestion that this 
modified enzyme is less sensitive to activation by phosphatases [111]. This idea is still 
somewhat controversial. More recently, Zhao et al. [112] reported on a proteomic analysis of 
the acetylation of lysine residues in human liver proteins. Included among the acetylated 
proteins identified was glycogen synthase, along with glycogen phosphorylase and UDP-
glucose pyrophosphorylase. Two modified lysine residues of glycogen synthase, Lys387 and 
Lys397, are conserved in metazoans, but not in yeast, and are located in the long helix that 
forms the tetramer interface (see below). Other acetylations are at Lys694, Lys695 and Lys696 
close to the C-terminus in a region of lower conservation. The ramifications of this novel 
finding for the physiological control of glycogen metabolism await further investigation.
Dephosphorylation of glycogen synthase, and other glycogen-metabolizing enzymes, is 
thought to be mediated by members of a family of glycogen-associated PP1Gs composed of 
a catalytic subunit (PP1c) bound to a glycogen-targeting subunit [113,114]. To date, seven 
such glycogen-targeting subunits have been identified by a combination of biochemical and 
bioinformatic analyses. Three of these targeting subunits have been more extensively 
studied. The RGL or GM subunit, product of the PPP1R3A gene, is restricted to skeletal and 
heart muscle [115]. The GL subunit, coded for by the PPP1R3B gene, is primarily expressed 
in the liver, but is also found in human muscle [116,117]. Its expression in liver is induced 
by insulin [118]. PTG (protein targeting to glycogen) (or R5), encoded by the PPP1R3C 
gene, is more ubiquitously expressed, and is found in several insulin-sensitive tissues, 
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including skeletal muscle, liver and fat [119]. PTG was proposed to act as a scaffold, 
interacting directly with glycogen synthase, glycogen phosphorylase and phosphorylase 
kinase [120], although other work questions this assessment [121]. Less is known of other 
family members. PPP1R3D (R6) is widely expressed, with high levels in heart and muscle, 
and lower levels in liver [122]. PPP1R3E is expressed predominantly in human heart and 
muscle, but in rat heart and liver [123]. Its hepatic expression was reduced in diabetic rats 
and the phosphatase activity associated with PPP1R3E was restored by administration of 
insulin [123]. Munro et al. [123] detected PPP1R3G mRNA only in brain, but a recent report 
described a role for PPP1R3G in liver glycogen metabolism, being paradoxically induced by 
fasting [124].
 Glycogen synthase structure
Like glycogenin, eukaryotic glycogen synthases are retaining glycosyltransferases that 
utilize UDP-glucose as the nucleotide-sugar donor. However, unlike glycogenin, they are not 
metal-ion-dependent and possess the other common glycosyltransferase core structure, the 
GT-B fold [125]. The GT-B fold is characterized by the presence of two Rossmann-fold 
domains with an interdomain cleft that harbours the active site. It is an interesting 
evolutionary observation that glycogen phosphorylase, which breaks down glycogen to 
glucose 1-phosphate, is also a member of the GT-B fold family, suggesting a divergent 
structural relationship for these enzymes that catalyse opposing reactions [126]. The overall 
GT-B fold is conserved between bacterial, archaeal and eukaryotic glycogen synthases [125–
128]. However, the eukaryotic enzymes differ in oligomeric state, specificity for nucleotide-
sugar donor, activation by glucose 6-phosphate and inactivation by phosphorylation.
Each of the distinct properties of the eukaryotic enzymes is associated structurally with 
sequence insertions or deletions relative to the bacterial and archaeal enzymes (Figure 6). A 
large insertion of approximately 100 amino acids is present in the C-terminal Rossmann-fold 
domain and forms the subunit interaction surfaces for the tetrameric eukaryotic glycogen 
synthases [125]. In addition to this large sequence insertion, a smaller insertion (residues 
481–492 in Gsy2p) forms a loop structure that provides the selectivity for UDP-glucose, 
rather than ADP-glucose, in eukaryotic forms. Regulation by phosphorylation is mediated 
through N- and/or C-terminal sequence extensions (Figure 5).
Surprisingly, the acquisition of glucose 6-phosphate regulation is not related to addition of 
structural elements as the binding site is composed of conserved secondary structure. Nor is 
it related to the glucose 6-phosphate-binding site in glycogen phosphorylase [129], where it 
is located in the N- rather than C-terminal Rossmann domain, although the conceptual 
framework for regulation by binding at a subunit interface and the involvement of multiple 
arginine residues anchoring the phosphate moiety is retained. The glycogen synthase glucose 
6-phosphate-binding site is created by a deletion, relative to bacterial and archaeal enzymes, 
within the loop connecting the N- and C-terminal domains (residues 225–235 in the 
Agrobacterium enzyme, Figure 6) and residue exchanges within the conserved elements of 
secondary structure. However, the ability to communicate this binding event between 
subunits requires the tetrameric interface that is generated by the large C-terminal sequence 
insertion mentioned above. The binding of glucose 6-phosphate within this interface triggers 
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a large subunit rotation and translocation at the subunit interface, such that the active-site 
clefts in the individual subunits are now open and accessible for glycogen binding [125] 
(Figures 7A and 7B). The driving force for this extensive conformational change is provided 
by relatively few contacts mediated by the glucose moiety of the allosteric activator (Figure 
7C). Glucose 6-phosphate is anchored into its binding site through five hydrogen-bonding 
interactions mediated by the phosphate moiety (Figure 7C), hydrophobic contacts with the 
faces of the glucose and a hydrogen bond to the 1′-hydroxy group. In contrast, a single 
hydrogen bond between the 2′-hydroxy group and His280 in the opposing subunit, as well as 
an interaction between adjacent Asn284 side chains, are the only strong contacts across the 
subunit interface that appear to stabilize the activated state (Figure 8).
A three-state model for Gsy2p activation was developed mainly on the basis of kinetic data 
[130]. Dephosphorylated enzyme in the absence of glucose 6-phosphate was in an 
intermediate basal-activity state. Phosphorylation decreased the activity, whereas addition of 
glucose 6-phosphate to either phosphorylated or unphosphorylated enzyme generated a 
high-activity state. Although structural information is available for the basal and activated 
states of yeast glycogen synthase, as noted above, information about the inhibited state is 
mostly through kinetic inference using the two available structural models as a basis for 
extrapolation (Figure 8). Phosphorylation occurs at serine/threonine sites outside the 
catalytic core (residues 2–630 of Gsy2p) of glycogen synthase to inactivate the enzyme 
(Figure 5). It is an interesting structural observation that the key regulatory arginine residues 
between residues 580 and 592 in Gsy2p are grouped on opposing sides of the same α-helix. 
Arg580, Arg583 and Arg587 are adjacent to the glucose 6-phosphate-binding site and form 
interactions with the allosteric activator, whereas Arg581, Arg589 and Arg592 lie on the 
opposing face of the helix and are oriented away from the protein surface [125]. Upon 
activation, the helices in which these arginine residues reside are pushed apart relative to 
their positions in the basal state conformation. By inference, we propose that the inhibited 
conformation positions these same helices closer together, creating a greater conformational 
tension to overcome in order to achieve an activated state. Evidence for this more closed 
state comes from two observations. First, mutation of the two arginine residues directed 
towards the helical interface (Arg589 and Arg592) to alanine renders the enzyme in a nearly 
inactive state (activity ratio of 0.11 [125]). Secondly, an alternative conformational state was 
observed for our basal-activity structure in which a sulfate, which could be mimicking a 
phosphate, is positioned between these regulatory helices and, when bound in this position, 
the helices are 3 Å (1 Å = 0.1 nm) closer than in the other basal-state conformation. Both 
observations suggest that charge neutralization of the arginine residues not involved in 
glucose 6-phosphate binding leads to a collapse of the regulatory helices toward each other 
at this crucial subunit interface, pushing the structure toward a more inhibited state. Like the 
charge neutralization due to sulfate binding or mutation, binding of a phosphorylated residue 
from the C-terminal (Gsy2p) or either the N-terminal or the C-terminal (higher eukaryotes) 
regulatory sequences to these same arginine residues would be expected to promote a similar 
collapse to the inhibited conformation. Because the conformational changes brought about 
by glucose 6-phosphate activation only affect the distance between the C-termini and 
regulatory helices in the opposing subunits, we favour a mechanism whereby the 
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phosphorylated residues are contributed across this interface from the opposite subunit and 
form a ‘locking strap’ to constrain the enzyme to its inhibited state [125].
An interesting property of glycogen synthase is that it remains associated with glycogen 
even when inactivated, such that both the dephosphorylated and phosphorylated forms of 
glycogen synthase can be recovered by simple precipitation of glycogen. This tight 
association with its substrate has led to speculation that the enzyme must possess some type 
of carbohydrate-binding module, such as those found in glycogen-binding subunits of PP1, 
laforin or the branching enzyme. However, simple sequence searches have failed to find such 
a distinct functional domain. When the first glycogen synthase structures were solved, the 
realization that it had the same protein fold as glycogen phosphorylase led to a thought that, 
like phosphorylase [131], perhaps glycogen synthase has its carbohydrate-binding sites 
integrated into its catalytic domain. Indeed, this has now been shown in the Escherichia coli, 
Pyrococcus abyssi and yeast Gsy2p enzymes [128,132,133]. These studies have revealed 
that glycogen phosphorylase and many forms of glycogen synthase retain a glycogen-
association site on the surface of their respective N-terminal Rossmann-fold domains that is 
completely independent of the acceptor binding site within the catalytic cleft (Figures 9A–
9C).
Gsy2p from S. cerevisiae has four such glycogen-association sites (Figure 9D): one is 
located on the surface of the N-terminal domain (site-1), two are located on the surface of 
the C-terminal domain (site-2 and site-3) and one is located near the interdomain cleft 
(site-4) that leads to the active site [133]. Conservation of amino acids within these 
glycogen-association sites in higher eukaryotes suggests that the mammalian enzymes 
possess these same sites. Mutational data, as well as yeast strain complementation 
experiments, indicate that all sites contribute to efficient utilization of glycogen as a 
substrate. However, site-4 appears to be unique in its ability to significantly affect the 
capacity of Gsy2p to utilize smaller oligosaccharides, such as malto-octaose, as an 
alternative acceptor substrate [133]. These findings support the idea that glycogen synthase 
integrates its carbohydrate-binding surfaces into the catalytic domain of the enzyme and 
these sites contribute to the high catalytic efficiency of glycogen synthase towards glycogen 
as its substrate.
It is likely that eukaryotic site-1–site-3 keep the enzyme tightly coupled to its substrate 
whether the enzyme is active or not, whereas site-4 serves a role in the proper positioning of 
the acceptor end within the active-site cleft, which apparently has a relatively low affinity for 
the acceptor end. This strategy solves the problem of rapid binding and release of actively 
extending chains, not requiring complete dissociation from glycogen to reset the position of 
the acceptor within the active site. It also increases the local concentration of non-reducing 
ends at or near the active site such that the lower affinity of the acceptor site does not 
negatively affect the overall efficiency of catalysis.
Díaz et al. [132] recently suggested that binding at accessory sites on the enzyme surface 
contributes to the processivity of glycogen synthase for chain elongation. Although this may 
be true, processivity towards a heterogeneous substrate such as glycogen is difficult to 
assess, since there are many non-reducing ends within a single glycogen particle where 
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catalysis can be directed without dissociation from the particle itself. The currently available 
data, including those of Baskaran et al. [133], would support this definition of processivity. 
However, there are no unequivocal methodologies currently available to assess the more 
strict definition of processivity where glycogen synthase remains associated with a single 
acceptor chain for multiple rounds of catalysis. The new elongation assay utilizing malto-
octaose as a substrate demonstrates a distributive mechanism for elongation of this substrate 
[133]. Thus processivity with respect to glycogen must be a function of the additional points 
of contact between the enzyme and this complex substrate.
 Catalytic mechanism and introduction of phosphate into glycogen by glycogen synthase
As mentioned for glycogenin, the chemical mechanism underlying catalysis in retaining 
glycosyltransferases remains an enigma. This is especially true for glycogen synthases. 
Unlike metal-dependent enzymes such as glycogenin, where a metal ion is the primary 
means through which the UDP leaving group is stabilized, glycogen synthases are metal-
ion-independent and rely on hydrogen bonds to amino acid side chains and main-chain 
atoms to provide charge stabilization of the UDP product (Figure 10). The available 
nucleotide-bound structures suggest that these roles are filled by conserved arginine and 
lysine residues (320 and 326 respectively in Gsy2p) and the helical dipole created by the N-
terminus of the helix (residues 513–521 in Gsy2p) immediately adjacent to the conserved 
glutamate residue (Glu509) that is strongly implicated in the glycosyl-transfer mechanism 
[128,134]. A number of catalytic roles have been proposed for this residue, including charge 
polarization of Lys326 for UDP stabilization, charge stabilization of the oxonium ion 
intermediate in an SN1/SNi mechanism, proper positioning of the glucosyl-donor sugar and 
as the catalytic nucleophile in an SN2 mechanism [126–128,134]. Whatever the precise role 
of this residue in the catalytic chemistry, it is clear that its presence in the active site 
contributes at least 104 towards the catalytic power of the enzyme and thus must be 
considered a nearly essential catalytic contributor.
Independent of the precise catalytic roles that active-site amino acids play in catalysis, the 
stereochemistry of the reaction dictates that the acceptor substrate is directed towards the 
same face of the glucosyl moiety from which the UDP leaving group departed. Thus the 
ability of the C-1 carbon atom to release the leaving group and undergo nucleophilic attack 
is an essential component of the reaction mechanism. However, there are other atoms of 
UDP-glucose that can undergo nucleophilic attack, including the phosphorus atoms in the 
diphosphate moiety. It has been proposed that the trace levels of phosphate found in 
glycogen arise from the inherent reactivity of the β-phosphate of UDP-glucose, leading to 
the incorporation of glucose-phosphate esters into glycogen [38].
Whelan’s group first reported an enzymatic activity from rabbit skeletal muscle that was 
capable of transferring the β-phosphate of UDP-glucose to glycogen [35]. However, the 
enzyme was never characterized at the molecular level. To assay and purify the proposed 
glycogen:glucose-1-phosphate transferase, Tagliabracci et al. [38] synthesized [β-32P]UDP-
glucose and demonstrated transfer of the β-phosphate from UDP-glucose to glycogen by a 
mouse muscle extract, but unexpectedly discovered that a muscle extract from a Gsy1−/− 
mouse {MGSKO (muscle-specific glycogen synthase-knockout) mouse [64]}, that lacks 
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glycogen synthase, did not catalyse this reaction. Purified glycogen synthases could also 
phosphorylate glycogen in vitro, with one phosphate introduced for every ~10000 glucose 
residues. This reaction might be viewed as an enzymatic error, not unlike those that occur 
during DNA and RNA biosynthesis [38]. The chemical mechanism for transfer of phosphate 
from UDP-glucose to the C-2 and C-3 hydroxy groups in glycogen awaits experimental 
confirmation, but it was speculated that it involves the formation from UDP-glucose of 
cyclic glucose phosphates (Figure 11), first described over 50 years ago by Paladini and 
Leloir [135]. Rarely, within the active site of glycogen synthase, the 2′ or 3′ hydroxy groups 
of UDP-glucose would spontaneously form glucose 1,2-cyclic phosphate or glucose 1,3-
cyclic phosphate through nucleophilic attack of the respective hydroxy groups on the β-
phosphate of UDP-glucose. At this point, the standard mechanism of glycogen synthase 
would operate, with attack by the activated C-4′ hydroxy group of the terminal glucose at the 
C-1 position of the cyclic phosphate, opening the ring to form a phosphoglucose that is 
added to the growing chain.
 Naturally occurring mutations of glycogen synthase and glycogen storage disease 0
Naturally occurring mutations in both GYS1 and GYS2 have been detected in humans. 
Mutation of GYS2, which causes hepatic glycogen deficiency, is better documented, and 
was named glycogen storage disease 0 (OMIM ID #240600). Patients have relatively mild 
symptoms, postprandial hyperglycaemia and fasting hypoglycaemia, consistent with the 
observed deficit in liver glycogen stores [136]. Hepatic glycogen synthase activity is 
reduced, consistent with the analysis of a number of the naturally occurring GSY2 mutations 
by expression in COS cells [137]. A mouse model, LGSKO (liver-specific glycogen 
synthase-knockout) mice, in which the Gsy2 gene is disrupted, reproduces much of the 
phenotype of the human disease [138]. The animals have mild fasting hypoglycaemia, but 
dispose glucose less well in a glucose-tolerance test. Fed animals have lower capacity for 
exhaustive exercise than their wild-type littermates, but the difference is lost after fasting. 
The mice have elevated basal gluconeogenesis and are predisposed to transition to the fasted 
state. Liver glycogen is therefore significant for normal blood glucose homoeostasis.
Loss-of-function mutations in muscle glycogen synthase have been reported in two families 
[139,140]. The disease has been designated muscle glycogen storage disease 0. In the first 
study [139], three siblings were identified with homozygous R462X mutations in GYS1. 
One sibling died of cardiac arrest at age 10.5 years and a second exhibited poor exercise 
performance and cardiac abnormalities at 11 years of age. Glycogen synthase and glycogen 
were absent from muscle. In the second case [140], an 8-year-old patient collapsed and died 
during exercise and was found to have a homozygous two-base deletion in exon 2 of GYS1. 
Many of the symptoms are consistent with cardiac problems observed with MGSKO mice in 
which Gys1 is disrupted [64,141]. In crosses of Gys1−/+ mice, 90% of the homozygous 
progeny died perinatally and had abnormal heart development. The surviving MGSKO mice 
had normal exercise capacity [142], normal lifespans with no overt cardiac symptoms and, 
paradoxically, enhanced glucose disposal in glucose-tolerance tests. It is likely that 
substantial developmental and metabolic differences between mice and humans underlie the 
observed discrepancies in phenotype between species. For example, in humans, it is possible 
that the perinatal mortality seen in mice can be delayed into early childhood. In any event, 
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this work underscores the possibility that GYS1 mutation may be an under-recognized cause 
for unexplained cardiac problems and deaths in newborns and young children.
In horses, PSSM (polysaccharide storage myopathy) has been recognized for many years as 
a debilitating glycogen storage disease prevalent in several genetically diverse breeds [143]. 
Breeding for desired traits in horses has also led to the concomitant accumulation of 
undesired genetic characteristics. PSSM is associated with excessive glycogen accumulation 
in muscle; symptoms vary widely, but can be very severe, leading to the inability of the 
animal to rise from a lying position. Recently, a mutation responsible for PSSM in multiple 
horse breeds was identified as an R309H-coding mutation in GYS1 and was associated with 
increased muscle glycogen synthase activity in the absence of the allosteric activator glucose 
6-phosphate, to generate a constitutively activated form of the enzyme. From inspection of 
the Gsy2p structure, this mutation is quite distant from the glucose 6-phosphate-binding site, 
but does occur at the interface between the catalytic domain and the long α-helices involved 
in subunit– subunit interactions. The mutation may therefore indirectly favour transition to 
the activated state, but more specific experiments would be needed to confirm this idea.
 REGULATION OF MUSCLE GLYCOGEN SYNTHESIS
 Rate-determining steps
Glycogen synthesis normally occurs after a meal, when blood glucose and insulin levels are 
elevated, or after exercise to restore depleted glycogen reserves. In muscle, a major issue is 
whether the rate of glycogen synthesis is determined by the rate of glucose entry into the cell 
or the activity of intracellular enzyme(s). In the terminology of MCA (Metabolic Control 
Analysis) [144], which steps have greatest flux control? Relatively few proteins are involved 
in the glycogen synthetic pathway (Figure 3) and the main candidates to control muscle 
glycogen synthesis are GLUT4, hexokinase and glycogen synthase. The other enzymes, i.e. 
phosphoglucomutase, UDP-glucose pyrophosphorylase, glycogenin and branching enzyme, 
do not appear to be either strongly regulated or rate-determining under normal 
circumstances. For many years, it was thought that dephosphorylation and activation of 
glycogen synthase by insulin was the dominant factor, following from the seminal study of 
Villar-Palasi and Larner [145]. This fundamental observation has been reproduced many 
times in animal- and cell-based experiments, and there is a good consensus on this point. 
When specialized glucose transporters were identified, attention focused also on glucose 
transport, especially with the finding that insulin promoted GLUT4 translocation to the 
plasma membrane in muscle [67]. Several mouse models have been constructed in which 
different components of the glycogen biosynthetic pathway have been mutated. The resting 
muscle glycogen content of a fed mouse provides a key primary index of the ability to 
synthesize glycogen under physiological conditions of insulin action. One of the earliest 
challenges to the primacy of glycogen synthase control came from transgenic overexpression 
of GLUT1 or GLUT4 in skeletal muscle which caused significant overaccumulation of 
glycogen [146,147]. However, muscle-specific knockout of GLUT4 paradoxically also led to 
elevated muscle glycogen [148]. The phenotype is ascribed to a variety of secondary effects 
in this mouse, including activation of PP1Gs with concomitant activation of glycogen 
synthase, and increased hexokinase leading to elevated glucose 6-phosphate. The complexity 
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of the phenotype made it difficult to assess the contribution of glucose transport to glycogen 
storage. Mice heterozygous for GLUT4-knockout, however, did exhibit decreased muscle 
glycogen levels [149]. Other mouse models have addressed glycogen synthase. Transgenic 
overexpression of glycogen synthase with two key inactivating phosphorylation sites (2a and 
3a) disabled (GSL mice) led to hyperaccumulation of glycogen in muscle [150]. More subtle 
genetic manipulation of glycogen synthase activity was achieved by overexpression [151] or 
knockout [152,153] of the gene encoding the PP1 glycogen-targeting subunit RGL so as to 
modify the phosphorylation state of glycogen synthase. Overexpression of RGL increased 
muscle glycogen approximately 3-fold, whereas the absence of RGL reduced muscle 
glycogen to 10% of wild-type. However, in these mice, the phosphorylation of both 
glycogen synthase and phosphorylase was modified. In humans, a common nonsense 
mutation in the PPP1R3A gene, which encodes RGL, was identified in 1.4% of the white 
population in the U.K. [154]. The mutation resulted in a truncated RGL protein and a 
decrease in muscle glycogen accumulation. A corresponding mutation engineered in mice 
reduced muscle glycogen by 50% and caused mis-targeting of RGL. In mice lacking the PTG 
PP1-targeting subunit, a ~30% reduction in muscle glycogen was observed [155]. An earlier 
study [156] had reported that homozygous disruption of PTG was lethal, but this result 
appears in contradiction to the more recent data. Other investigations sought to manipulate 
glycogen synthase phosphorylation via protein kinases. This approach is a priori complex, 
since multiple protein kinases can phosphorylate glycogen synthase and multiple sites can 
influence activity (Table 2). Muscle-specific disruption of the gene encoding GSK3β 
resulted in a 2-fold increase in glycogen accumulation, with an increase in glycogen 
synthase activation by insulin, but no effect on glucose transport; the animals had improved 
glucose disposal and insulin-sensitivity [108]. Taken together, the preceding results with 
mouse models suggest that genetic modulation of either glucose transport or glycogen 
synthase activity is capable of affecting muscle glycogen stores.
Shulman and colleagues have addressed this question using a combination of in vivo NMR 
and MCA [157–159]. Their conclusion was that, within the formalism of MCA, flux control 
was concentrated at the stage of glucose transport. They argue that glycogen synthase 
activation via dephosphorylation serves not to increase the metabolic flux to glycogen, but 
rather to allow a higher glycogen synthetic rate without elevation of glucose 6-phosphate 
levels [160]. It was pointed out many years ago that there is limited solvent capacity in cells 
and that it is therefore necessary to minimize metabolite concentrations [161]. Another 
MCA analysis of insulin-stimulated glycogen synthesis in rat muscle indicated flux control 
distributed between transport and synthesis [162]. So, where are we in resolving this issue? 
The different experimental approaches have their advantages and drawbacks. Genetically 
modified mice have the power of any genetic system, but suffer from the possibility of 
adaptive responses to the gene modifications; a kind of biological Heisenberg uncertainty 
principle, if you will. The elegance of non-invasive analysis of glycogen metabolism by 
NMR has to be balanced with its limitations [163], which include sensitivity and inability to 
address spatial heterogeneity. The application of MCA in complex animal models is also 
based on necessarily simplistic assumptions. We would argue that regulation, defined as an 
evolved mechanism to modify activity, of both glucose transport and of glycogen synthase 
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can contribute to the rate of glycogen accumulation, possibly to different extents that may 
vary under different circumstances [164].
 Mechanism of glycogen synthase activation by insulin
More challenging has been the effort to determine which of the in vitro protein kinases 
and/or phosphatases mediate the activation of glycogen synthase by insulin (Figure 12). 
GSK3, whose action potently inactivates glycogen synthase in vitro by phosphorylation of 
four C-terminal sites [165], has long been considered an important candidate to regulate 
glycogen synthase. Insulin controls GSK3 activity by promoting phosphorylation of its N-
terminal inhibitory phosphorylation site via the Akt/PKB pathway, by a well-established 
mechanism [166,167]. Insulin thus inactivates GSK3, leading to decreased phosphorylation 
at its target sites in glycogen synthase due to phosphatase action. Muscle-specific knockout 
of GSK3β in mice increased glycogen levels and potentiated insulin-mediated activation of 
glycogen synthase [108]. Conversely, overexpression of GSK3β in muscle resulted in 
reduced glycogen accumulation and reduced the glycogen synthase activation state [168]. 
Earlier studies had suggested that insulin caused dephosphorylation of both N- and C-
terminal phosphorylation sites of glycogen synthase [169,170]. The argument was therefore 
made that insulin must promote dephosphorylation of non-GSK3 sites by other mechanisms 
(see, for example, [12]). Possibilities would include inactivation of a site 2 kinase, for which 
there are numerous candidates (Table 2), or activation of a phosphatase, probably of the 
PP1G family. Knockout of the gene encoding either RGL [152,153] or PTG [155] reduced 
basal glycogen synthase activity and glycogen accumulation, but did not disable insulin-
mediated activation of glycogen synthase. If a phosphatase is involved, it must involve a 
different regulatory subunit. Another potential complication is redundancy of protein kinases 
for a given site. For example, in COS cells, sites 3a and/or 3b of glycogen synthase can be 
phosphorylated by a mechanism independent of GSK3 [95]. There are three candidates from 
in vitro experiments, a DYRK (dual-specificity tyrosine-phosphorylated and -regulated 
kinase) family kinase [171], p38β [172] and PASK [PAS (Per/Arnt/Sim) domain-containing 
protein kinase] [173]. Some of the uncertainty may have been resolved by the study of 
McManus et al. [174] who made knockin mice in which either or both GSK3α and GSK3β 
had their inhibitory N-terminal phosphorylation sites (Ser21 and Ser9 respectively) mutated 
to alanine. Surprisingly, muscle glycogen levels were unaffected in the double-knockin 
homozygous mice in which GSK3 is constitutively active. Basal glycogen synthase activity 
was also unchanged, as was phosphorylation of key GSK3 sites, Ser641 and Ser645, but 
insulin-stimulated activation of glycogen synthase was suppressed. The authors argue that 
the results prove not only that GSK3 (in particular GSK3β) is the primary means by which 
insulin activates muscle glycogen synthase, but also that no other protein kinases, 
phosphatases, or phosphorylation sites are involved unless they too are controlled by GSK3. 
Perhaps the latter conclusion is a little strong since insulin did activate glycogen synthase in 
GSK3β muscle-specific knockout mice without compensatory changes in GSK3α protein 
levels or insulin-induced phosphorylation [108]. Therefore there may still be room for 
GSK3-independent controls of glycogen synthase activity by insulin, but the GSK3-knockin 
mouse models make a strong case for the importance of GSK3 in insulin signalling to 
glycogen synthase.
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 Mechanism of glycogen synthase control by exercise
Exercise depletes glycogen which must subsequently be replenished, requiring activation of 
glycogen synthesis (Figure 12). Depending on the experimental conditions, both inactivation 
and activation of glycogen synthase have been observed in response to exercise [175,176]. 
Furthermore, activation has been observed both during exercise and after its cessation [175]. 
Activation of glycogen synthase could be considered paradoxical since this is, overall, a 
period of glycogen utilization. Several rationalizations can be advanced: (i) activation could 
‘prime’ glycogen synthase for rapid glycogen synthesis once contractile activity lessens; (ii) 
other factors besides phosphorylation may prevail to avoid glycogen synthesis and ‘futile 
cycling’ of glycogen; and (iii) glycogen is actually synthesized and utilized during exercise 
[177]. Nielsen and Richter [175] have emphasized how various negative and positive signals 
elicited during exercise must be integrated to determine glycogen synthase activity. Still, the 
exact mechanism for how exercise controls glycogen synthase phosphorylation is not yet 
clear, although there is probably a consensus that it differs significantly from insulin-
mediated regulation. First, exercise-induced activation of glycogen synthase occurs in 
muscle-specific insulin-receptor-knockout mice [178]. Secondly, exercise activation of 
glycogen synthase is normal in the GSK3-double-knockin mice described above [174]. 
Knockout of the PP1 glycogen-targeting subunit RGL in mice does block activation of 
glycogen synthase by exercise or in situ electrical stimulation, suggesting a role for the 
phosphatase [151]. How RGL is regulated is not known. An earlier model had proposed that 
PKA (protein kinase A), activated by adrenaline (epinephrine), phosphorylates RGL and 
causes its dissociation from the glycogen particle [179]. However, during exercise, the PKA 
pathway is likely to be activated, which would decrease phosphatase activity in this model.
The relationship between glycogen synthase phosphorylation and activity during muscular 
activity is complex and exemplifies the notion that inhibitory and activating signals can 
converge. It has been observed that exercise causes both phosphorylation of sites 2 and 2a, 
correlating with decreased activity, whereas, upon more prolonged activity, sites 3a and 3b 
are dephosphorylated, resulting in a net activation [176,180]. Dephosphorylation of sites 3a 
and 3b could result from the action of RGL-PP1c, as described above. Site 2, in vitro, is a 
substrate for multiple protein kinases (Table 2), several of which could conceivably be 
activated under conditions of muscle contraction. Phosphorylase kinase and AMPK are 
known to associate with glycogen and have well-established mechanisms for activation 
during exercise. Phosphorylase kinase is activated by Ca2+ and PKA. PKA is activated by 
cAMP, whose level is likely to be increased under conditions of glycogenolysis. Note also 
that phosphorylation of a C-terminal PKA site, site 1b, may have a function in the 
translocation of glycogen synthase (discussed below). Furthermore, CAMKII (Ca2+ /
calmodulin-dependent protein kinase II) is also activated by Ca2+.
Attention has been paid recently to the possible role of AMPK as a site 2 kinase. AMPK, 
whose activity increases with depletion of the adenylate pool for ATP, is thought to be a 
monitor of cellular energy status [181] and is indeed activated by muscular activity [182]. 
AMPK phosphorylates glycogen synthase in vitro [183], and disruption of the gene 
encoding the α2-subunit, but not the α1-subunit, of AMPK resulted in decreased basal 
phosphorylation of glycogen synthase at site 2 + 2a by ~60% and increased its activation 
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state [184]. AICAR (5-amino-4-imidazolecarboxamide riboside), an oft used, although 
relatively non-specific, activator of AMPK, caused a modest increase in site 2 
phosphorylation that was not seen in the α2-knockout muscle [184]. The β-subunit of 
AMPK, as noted, contains a CBM20 domain that allows it to bind glycogen, certainly in 
vitro [51,52,185]. There is some controversy over the stability of the association and its 
effects on activity. Stapleton and colleagues attempted to isolate glycogen using relatively 
gentle methods and could not document co-purification of the β-subunit [45,186]. They had 
previously failed to show inhibition of AMPK activity by glycogen [52]. However, the study 
of McBride et al. [185] provides fairly compelling evidence for inhibition of AMPK activity 
in vitro by glycogen, although they note some variability between glycogen preparations. 
Their bovine liver glycogen inhibited half-maximally at 30 mM glucose equivalents. Smaller 
oligosaccharides also bound and some could inhibit depending on their structure. For 
example, linear oligosaccharides such as maltohexaose or maltoheptaose bound, but did not 
inhibit, AMPK, whereas synthetic oligosaccharides containing an α-1,6-linkage were 
effective inhibitors in the 100–200 μM range. This observation led McBride et al. [185] to 
propose that AMPK bound to extended outer chains of glycogen would be active and able to 
phosphorylate and inactivate glycogen synthase, whereas glycogen with outer chains 
degraded by phosphorylase, would have more exposed α-1,6-linkages that could inhibit 
AMPK, leading to activation of glycogen synthase. Of course, one weakness in this 
hypothesis is that, in vivo in the presence of debranching enzyme AGL, phosphorylase-limit 
outer chains would surely have a fleeting existence. Also, site 2 phosphorylation alone 
cannot fully inactivate glycogen synthase. The broader notion, that AMPK acts as a sensor 
of glycogen, is, however, appealing. It could help to explain the inverse correlation between 
glycogen synthase activation state and glycogen level that goes back to the early study of 
Danforth [187]. Particularly in muscle, there is a correlation between increased AMPK 
phosphorylation (and presumably activity) and decreases in glycogen level caused by 
exercise [182] or genetic manipulation [141]. In liver, matters may be less clear since 
depletion of glycogen in the LGSKO mice, if anything, decreased AMPK phosphorylation 
[138]. The concept of glycogen level and concentration is itself a particularly difficult one, 
as acknowledged by McBride and Hardie [188]. Even without invoking differences in 
affinity for particular oligosaccharide structures, the surface of a large glycogen particle is 
likely to be very different than that of a smaller one, presenting a different local 
concentration, if you will, of chains to inhibit or not inhibit AMPK. Future work will require 
clever experiments to test this intriguing hypothesis.
A rather different connection between AMPK and glycogen comes from study of Hampshire 
pigs [189] and PRKAG2 (AMPK γ2 non-catalytic subunit) mutations in humans [190] which 
cause massive overaccumulation of glycogen in muscle and heart respectively. In the pigs, 
excess glycogen has a deleterious effect on meat quality. In humans, it causes PRKAG2 
cardiomyopathy. The mutations are in the γ3 and γ2 subunits of AMPK respectively, and, 
although there has been some debate, it appears that the mutations are effectively gain-of-
function [190]. That such mutations cause increased glycogen storage cannot be easily 
reconciled with glycogen synthase phosphorylation at site 2. In addition, in some studies, 
AMPK activation by exercise correlates with activation of glycogen synthase [151,191]. It is 
possible that a different function of AMPK is involved, such as its role in autophagy, as 
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discussed below, or its stimulation of glucose transport in muscle. It remains to be 
established whether AMPK is really a predominant glycogen synthase site 2 kinase.
 Allosteric compared with covalent control of glycogen synthase
Since glycogen synthase is regulated by both phosphorylation and allosteric activation by 
glucose 6-phosphate, the relative importance of these mechanisms has been much discussed, 
especially for liver where glucose 6-phosphate is believed to play an important role in 
driving glycogen synthesis [7,14,17]. Pederson et al. [130] used an alanine-scanning 
mutagenesis approach to identify basic residues of yeast Gsy2p involved in activation by 
glucose 6-phosphate. Two mutant enzymes were identified that, in vitro, were unaffected by 
glucose 6-phosphate; one retained inactivation by phosphorylation and the other was 
unaffected by phosphorylation. The mutations were of arginine residues in the highly 
conserved arginine cluster (Figure 5) that is involved in binding glucose 6-phosphate and 
setting the activity state of the enzyme (Figures 7 and 8). Expression of the unregulated 
mutant Gsy2p in yeast resulted in hyperaccumulation of glycogen, whereas the mutant that 
retained phosphorylation control accumulated less glycogen than wild-type enzyme [192]. 
The study provided evidence for the importance of glucose 6-phosphate in normal glycogen 
synthesis in vivo and also affirmed the relevance of phosphorylation in the absence of 
glucose 6-phosphate control [192]. A more recent discussion of mammalian systems began 
with the work of McManus et al. [174], discussed above, on the double-knockin 
homozygous mice with constitutively active GSK3 in which glycogen levels were normal. 
Bouskila et al. [193] suggested that, in these double-knockin mice, glucose 6-phosphate 
control might be the key reason for the normal glycogen accumulation. Hanashiro and 
Roach [194] had transferred the glucose 6-phosphate-desensitizing mutations studied in 
yeast Gsy2p to mammalian glycogen synthase and Bouskila et al. [193] refined the analysis 
to identify R582A and R586A as point mutations that conferred insensitivity to glucose 6-
phosphate activation, sensitivity to phosphorylation and the ability to be normally expressed 
in mammalian cells. A Gys1-knockin mouse encoding the R582A mutation was then 
constructed. Muscle glycogen levels were ~50% of wild-type, demonstrating that glucose 6-
phosphate activation of glycogen synthase plays an important role in glycogen metabolism. 
This result, in fact, is quite similar to what was observed in yeast [192]. The muscle from the 
R582A mice had elevated glucose 6-phosphate and UDP-glucose levels, consistent with 
diminished flux towards glycogen, and ex vivo analyses of muscles indicated reduced 
insulin-stimulated glycogen synthesis. Bouskila et al. [193] concluded that insulin 
stimulation of glycogen synthesis in muscle is driven predominantly by elevation of glucose 
6-phosphate, not glycogen synthase dephosphorylation. Hunter et al. [195] reported that 
AICAR-induced glycogen synthesis was abolished in the R582A mice, arguing that glucose 
6-phosphate was driving glycogen accumulation. These studies raise interesting questions. It 
would be useful to revisit the role of phosphorylation control using knockin of glycogen 
synthase mutated at site 2 and/or 3a to see whether the results mimic the earlier less 
sophisticated GSL mouse models that used transgenic overexpression [150].
Roach et al. Page 19
Biochem J. Author manuscript; available in PMC 2016 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 SPATIAL ASPECTS OF GLYCOGEN METABOLISM
 Heterogeneity of glycogen stores in cells and tissues
Glycogen is usually described as primarily cytosolic. In typical biochemical fractionations 
of extracts of tissue or cells, the bulk of the glycogen remains in a low-speed supernatant 
after centrifugation, although some is in the pellet, depending on the biological source and 
metabolic conditions. Glycogen particles are large enough that high-speed centrifugation of 
the low-speed supernatant can sediment them into a high-speed pellet, together with 
membranous structures. Although it is possible and even likely that small-molecule 
metabolites are not homogeneously distributed within cells, it is especially easy to make the 
case with glycogen, since it can be visualized by electron microscopy as discrete particles, 
each one a potentially autonomous metabolic machine. In skeletal muscle, cellular 
localization leads to the definition of distinguishable pools of glycogen granules, 
sarcolemmal, intermyofibrillar and intramyofibrillar [57,196]. Graham and colleagues have 
pioneered efforts to quantify these subcellular pools (reviewed in [15,19]), and evidence is 
emerging that different pools may have different metabolic behaviours [197,198]. A further 
level of heterogeneity enters when one considers entire tissues. Different muscle fibre types, 
which can be intermingled in any given muscle, can have different metabolic regimes [199], 
glycogen metabolism being more important in fast twitch type II fibres. In the liver, 
periportal and perivenous hepatocytes have significantly different metabolic capacities [200], 
including differences in the metabolism of glycogen [201]. Obviously, measurements of 
glycogen by gross biochemical or NMR methods cannot address such heterogeneity.
 Translocation of metabolic enzymes during glycogen synthesis
In liver, it is generally accepted that glucose entry into cells is driven by the concentration 
gradient between the blood and the hepatocyte, based on the kinetic properties of the high-
Km GLUT2 [67]. Unlike the hexokinase of muscle, the liver glucokinase (hexokinase IV) is 
not inhibited by its product glucose 6-phosphate, but by a separate regulatory protein [GKRP 
(glucokinase regulatory protein)] [202]. Glucokinase, under basal glucose conditions, is 
sequestered in the nucleus where it is bound to GKRP and is held inactive [202]. Acute 
activation of glucokinase involves its glucose-induced translocation from the nucleus to the 
cytosol. Guinovart and colleagues have championed the idea that hepatic glycogen synthase 
also translocates upon exposure of hepatocytes to glucose towards the cell periphery, where 
new glycogen is synthesized at the site of glucose entry (reviewed in [14]). Glucose 6-
phosphate appears to be critical to the translocation process as well as being a direct 
activator of glycogen synthase.
Hers and colleagues (reviewed in [203]) many years ago proposed a mechanism whereby 
glycogen phosphorylase and synthase phosphorylation states were controlled in an 
interdependent fashion in the liver. Central to this hypothesis was allosteric inhibition of 
glycogen synthase phosphatase by the phosphorylated and active form of phosphorylase. 
Thus activation of glycogen synthase by a glycogenic stimulus would only be enabled once 
phosphorylase was first inactivated. Cohen and colleagues revisited this concept armed with 
more modern understanding of the nature of the phosphatases likely to be involved 
[116,117]. A predominant glycogen synthase phosphatase in liver consists of the PP1 
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catalytic subunit in association with the GL glycogen-targeting subunit [116,117]. 
Armstrong et al. [121] localized the phosphorylase interacting sequence to the C-terminal 16 
amino acids of GL and Kelsall et al. [204] showed that mutation of Tyr284 to phenylalanine 
disrupted binding to phosphorylase. Kelsall et al. [205] went on to produce Y284F-knockin 
mice and demonstrated that liver glycogen was increased modestly, but both glycogen 
synthase and phosphorylase activities were significantly increased. In vitro assays showed 
that thiophosphorylase was unable to inhibit the glycogen synthase phosphatase activity of 
mutant GL-PP1c. There was an improvement in glucose disposal in the Y284F mice, 
especially in males, leading to efforts to target interference of the GL–phosphorylase 
interaction as a therapeutic approach for Type 2 diabetes [206].
Translocation of glycogen synthase has also been observed in other cells. Cid et al. [207] 
showed that the muscle glycogen synthase isoform was localized in the nucleus in several 
cell types, including primary human myoblasts, when glucose was low or absent, but was 
cytosolic in punctate structures in the presence of glucose. Interestingly, phosphorylation 
does not appear to be relevant to this nuclear localization whereas the arginine-rich cluster is 
important. In S. cerevisiae, glycogen synthase localization correlated strongly with cellular 
glycogen content [208], changing from a uniform distribution in the cytoplasm when 
glycogen was abundant to discrete well-defined spots when glycogen was scarce. In a strain 
lacking glycogenin, and hence unable to synthesize glycogen, Gsy2p was nuclear, echoing 
the results discussed above. In yeast, however, mutation of the arginine-rich cluster did not 
affect nuclear localization. Other studies have linked glycogen synthase phosphorylation to 
subcellular distribution. In 3T3-L1 adipocytes, Ou et al. [209] reported that insulin caused 
activation of glycogen synthase accompanied by a shift from a diffuse distribution to 
punctate cytosolic structures. Other correlations between glycogen synthase phosphorylation 
and subcellular localization have come from studies of rabbit and human muscle. Prats et al. 
[210] reported that, after glycogen depletion by electrical stimulation, rabbit muscle 
glycogen synthase dephosphorylated at site 1b and sites 2 + 2a redistributed to specialized 
spherical structures as a prelude to resynthesis. In a subsequent study of human muscle, 
further correlation between glycogen synthase phosphorylation and subcellular localization 
was made [211]. Enzyme phosphorylated at site 1b was mainly associated with 
intramyofibrillar particles, whereas phosphorylation at site 2 + 2a was associated with 
intermyofibrillar and subsarcolemmal particles. It was proposed that site 1b phosphorylation 
was mediated by adrenaline activation of PKA following exercise. This would provide a 
function for site 1b, which has no direct effect on activity and which is absent from liver 
glycogen synthase.
 Lysosomal disposal of glycogen
Cytosolic degradation of glycogen by phosphorylase and debranching enzyme AGL has 
commanded much attention, perhaps because it has been such fertile ground for the 
discovery of biochemical and hormonal mechanisms. However, glycogen is also disposed 
via a lysosomal pathway, the importance of which is underscored by Pompe disease 
(glycogen storage disease type II), in which the lysosomal α-glucosidase (GAA) is mutated 
[74]. Glycogen overaccumulates in lysosomes and vesicular structures [212]. In its most 
severe form, Pompe disease is fatal within the first year of life, with cardiomyopathy and 
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muscular hypotonia (OMIM ID #232300). It has been reported that as much as 10% of 
hepatocyte glycogen is present in the lysosome [28,213]. The exact mechanism by which 
glycogen is normally transferred to the lysosome is unknown, but is most likely to involve 
some autophagic or autophagy-like vesicular trafficking (Figure 13). Autophagy comprises a 
family of processes initially described as a mechanism for random recycling of cellular 
materials under conditions of nutritional deprivation [214,215]. The type of autophagy that 
has been most studied, macroautophagy, involves engulfment of cargo within a double 
membrane to form autophagosomes that ultimately fuse with the lysosome where the cargo 
is degraded [214–216]. From the intense research activity in this area, it is becoming clear 
that there are many variants of the basic autophagic process that can have separate controls, 
specific cargoes and different functions [217,218]. Glycogen has been linked specifically to 
autophagy. The term ‘glycogen autophagy’ has been applied particularly to the liver of 
newborns (reviewed in [219]). Glycogen has been reported to accumulate in several organs, 
notably liver and heart, of the fetus before term, presumably to provide energy reserves for 
use after the trauma of birth [220]. For the liver, and the newborn in general, the hepatic 
glycogen reserves are especially important since gluconeogenesis is not well developed at 
birth [220] and therefore lysosomal degradation of liver glycogen is critically important. 
Another connection with autophagy is provided by the work of Raben et al. [221] on Pompe 
disease. From studies of muscle in a mouse model of Pompe disease, GAA−/− mice, they 
have shown that massive overaccumulation of glycogen in lysosomes, characteristic of the 
disease, was accompanied by a dramatic increase of glycogen-containing autophagosomes 
and late endosomes, which they referred to as ‘autophagic build-up’ [221]. Subsequently, 
mice were generated that combined a homozygous null GAA mutation with muscle-specific 
disruption of the genes encoding Atg5 [222] or Atg7 [223], important autophagy proteins. 
Loss of Atg5 function indeed diminished autophagic build-up in muscle, but made the 
clinical phenotype worse. Loss of Atg7 had a similar effect and decreased glycogen by 50–
60%. Enzyme replacement therapy (delivery of GAA directly to the animals) normalized 
glycogen levels in the autophagy-deficient mice [223], making selective suppression of 
autophagy a promising therapeutic approach for Pompe disease patients.
A totally different link between glycogen and autophagy came from analysis of yeast 
glycogen metabolism where an unbiased genetic screen showed that two prototypical yeast 
autophagy genes, ATG1 and ATG13, could restore defective glycogen accumulation to a 
snf1 mutant strain [224]. In yeast, defective Snf1p, the orthologue of mammalian AMPK 
catalytic subunit, causes failure to accumulate glycogen. Snf1p was then found to be a 
positive regulator of autophagy acting upstream of Atg1p; in yeast, transport of glycogen to 
the vacuole, the approximate equivalent of the mammalian lysosome, actually serves to store 
glycogen which is only used very late in starvation, possibly for sporulation, when the yeast 
vacuolar GAA is induced. A genome-wide survey of yeast for genes whose deletion affected 
glycogen metabolism revealed that the second largest category of genes identified, ~60, were 
involved in some way in vesicular trafficking or vacuolar function [225]. Subsequent studies 
of mammalian autophagy showed that AMPK is also a positive regulator of autophagy [226] 
and, more recently, implicated AMPK as an upstream regulator of ULK1 [227–230], a 
mammalian orthologue of Atg1p [231]. One might speculate whether activating mutations of 
the AMPK γ-subunit might be causing excessive autophagy that is associated with the 
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pathological overaccumulation of glycogen, via mechanisms such as described below. If a 
downstream trafficking event, for example, the fusion of glycogen-laden autophagosomes 
with the lysosome, became limiting, there could be a build up of glycogen vesicles such as is 
seen in PRKAG2 cardiomyopathy or Pompe disease.
Mechanistically, how is glycogen transported to lysosomes? If vesicular transport is 
involved, one would expect a means to associate glycogen with membranes. Using electron 
microscopy, glycogen particles are often reported to be close to membranes, endoplasmic 
reticulum in liver [232] or sarcoplasmic reticulum in muscle [15]. Recently, Stbd1 has 
emerged as a candidate to anchor glycogen to membrane locations [55]. In independent 
work, Stbd1 was identified as being associated with liver glycogen in a proteomics study and 
proposed to be involved in locating glycogen to membrane compartments in cells [45]. 
Stbd1 has a highly conserved N-terminal 24-residue hydrophobic sequence and a C-terminal 
CBM20 domain [233], with an intervening sequence predicted to be disordered [55]. In 
vitro, Stbd1 binds to polysaccharides, preferentially interacting with less branched structures 
such as the amylopectin of plant starch or the glycogen isolated from laforin-knockout mice 
(see the next section). In MGSKO and LGSKO mice, lacking muscle and liver glycogen 
respectively, Stbd1 levels are decreased, suggesting a connection between Stbd1 and 
glycogen metabolism. Expression of Stbd1 in COS cells resulted in the formation of large 
perinuclear structures, as judged by immunofluorescence, co-localized with glycogen 
identified by PAS staining [55]. Point mutations in the CBM20 domain designed to disable 
glycogen binding did not alter Stbd1 perinuclear localization, but eliminated glycogen co-
localization. Deletion of the hydrophobic N-terminus of Stbd1 led to a diffuse cytosolic 
distribution, supporting the idea that it serves to direct Stbd1 to intracellular membranes.
This first effort at assessing the function of Stbd1 provides plausible evidence for a role in 
glycogen metabolism, with the hypothesis that Stbd1 anchors glycogen to intracellular 
membranes. Yeast two-hybrid screens using Stbd1 as bait identified Stbd1 itself as an 
interacting protein, suggesting an oligomeric structure, GABARAP (γ-aminobutyric acid 
type A receptor-associated protein) and GABARAPL1 (GABARAP-like 1). The last two are 
members of the mammalian ATG8 family of autophagy proteins [234,235]. Interaction of 
both GABARAP and GABARAPL1 with Stbd1 was validated by co-expression in COS 
cells and co-immunoprecipitation. By immunofluorescence, Stbd1 was strongly co-localized 
with GABARAPL1, less so with GABARAP, in the perinuclear structures described above. 
Similar co-localization was observed between Stbd1 and endogenous GABARAPL1. The 
association between Stbd1 and GABARAPL1 provides a tantalizing connection with 
autophagy. Yeast have a single ATG8 gene that is thought to be critically involved in the 
formation of autophagosomes [234]. The emerging sense is that selectivity can be conferred 
by interaction of Atg8 with specific receptor proteins [217,218]. In mammals, the situation is 
more complex as there are six orthologues of Atg8, the best studied being LC3 (light chain 
3), whose lipidation is often used as a marker for autophagy induced by nutritional stresses 
[236]. The interaction of ATG8 family members with different cargo-specifying receptors 
may thus allow for a variety of selective autophagy pathways whose operation need not 
mimic exactly the traditional macroautophagy process mediated by LC3. Little is known 
about the function of GABARAPL1 [237]. A current hypothesis, then, is that Stbd1 tethers 
glycogen to membranes and, by an as yet undefined mechanism involving interaction with 
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GABARAPL1, participates in the trafficking of glycogen to the lysosome, the process of 
‘glycogen autophagy’ or ‘glycophagy’. Since Stbd1 in vitro shows a preference for binding 
to poorly branched and/or highly phosphorylated glycogen, it could favour the disposal of 
aberrant glycogen particles and be part of a quality-control mechanism. Alternatively, it 
might be controlled by conditions or stimuli that tend to produce aberrant glycogen. Much 
remains to be learned about the function of Stbd1 and the phenotype of an Stbd1-knockout 
mouse, currently under construction, will be of considerable interest.
 LAFORA DISEASE AND GLYCOGEN PHOSPHORYLATION
A century ago, Gonzalo Lafora reported autopsy results from patients with teenage-onset 
myoclonus epilepsy with associated dementia [238]. He observed in ganglion cells ‘amyloid 
bodies’, a term used at the time to describe material that stained like starch. We now know 
that these ‘Lafora bodies’ are actually deposits that contain poorly branched insoluble 
glycogen-like carbohydrate, sometimes called polyglucosan, and are a hallmark of Lafora 
disease, an autosomal recessive fatal neurodegenerative disorder categorized as a progressive 
myoclonus epilepsy. Symptoms start in early adolescence and progress as stimulus-sensitive 
grand mal tonic–clonic, absences, and visual and myoclonic seizures. Rapid progressive 
dementia develops leading to death typically within 10 years of the first symptom [39–
41,239]. Lafora disease is very rare, found most often in parts of the world where 
consanguinity is common [240]. Lafora bodies are found in many tissues, including the 
brain, skeletal muscle, heart and liver; their presence in neurons is widely considered 
causative of the disease. Mutations in two genes, EPM2A (epilepsy progressive myoclonus 
type 2A) and EPM2B (epilepsy progressive myoclonus type 2B), account for approximately 
90% of Lafora cases [241]. EPM2A or EPM2B encode the proteins laforin and malin 
respectively.
 Laforin
Minassian et al. [53] identified the laforin gene by positional cloning. Laforin is ubiquitous, 
with the highest expression levels in skeletal muscle, liver, kidney, heart and brain, tissues 
with abundant Lafora bodies in Lafora patients [54,242]. Laforin contains the signature DSP 
(dual-specificity phosphatase) catalytic motif, HCXXGXXRS/T [243], and can 
dephosphorylate phosphoserine/phosphothreonine, phosphotyrosine [244] and the generic 
phosphatase substrate PNPP (p-nitrophenyl phosphate) in vitro [245]. Additionally, laforin 
contains a CBM20 domain that binds complex carbohydrates including glycogen, 
amylopectin and polyglucosan [245–247]. Laforin is conserved in all vertebrates and in a 
small defined group of invertebrates and protists, including Toxoplasma gondii, that are of 
red algal descent, possess a true mitochondrion and produce floridean starch, a complex 
carbohydrate resembling amylopectin [248,249].
In mammals, laforin has been reported to bind several proteins involved in glycogen 
metabolism, including glycogen synthase, GSK3, PTG and malin [250–253]. HIRIP5 
[HIRA (histone cell cycle regulation defective homologue A)-interacting protein 5], a 
cytosolic protein involved in iron metabolism [254], Epm2a-interacting protein 1, a protein 
with unknown function [255], the Alzheimer’s disease protein tau [256], and the α2 and β2 
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subunits of AMPK [257] also interact with laforin. Some 59 disease-causing mutations and 
several polymorphisms in the EPM2A gene have been described. Of those tested, almost all 
affect polysaccharide binding or phosphatase activity (The Lafora Progressive Myoclonus 
Epilepsy Mutation and Polymorphism Database; http://projects.tcag.ca/lafora/). One 
mutation was described that had no effect on phosphatase activity and polysaccharide-
binding activity, but was reported to affect interaction with PTG [251]. Laforin is extremely 
sensitive to inhibition by polysaccharides, when assayed using PNPP, but 20% of activity 
remains at saturation [247]. One disease mutation, W32G [258], is located in the conserved 
carbohydrate-binding domain and the recombinant phosphatase harbouring this mutation 
eliminates glycogen binding while retaining significant PNPPase activity [245,247]. 
Therefore impaired glycogen binding by laforin may be sufficient to cause disease. Another 
link between laforin and glycogen comes from the observation that laforin protein levels 
correlate with the amount of glycogen in a series of mouse models in which the muscle 
glycogen content was genetically manipulated [259].
A prominent hypothesis in Lafora research has been that polyglucosan formation results 
from an imbalance between the activities of glycogen synthase and branching enzyme. 
There is precedent since polyglucosans accumulate in other glycogen storage diseases. For 
example, Andersen disease and adult polyglucosan body disease both result from mutations 
in the GBE1 gene, encoding the branching enzyme [260]. Impaired branching activity leads 
predictably to a less branched form of glycogen. In Tarui disease [261], the PFKM gene, 
encoding the muscle form of phosphofructokinase, is mutated. A build-up of glycolytic 
intermediates in Tarui patients is thought to drive excessive glycogen synthesis through 
elevation of glucose 6-phosphate, also resulting in polyglucosan formation, the imbalance in 
this case caused by increased glycogen elongation. In the GSL mice, described earlier, 
which overexpress hyperactive glycogen synthase in muscle, overaccumulation of glycogen 
is accompanied by the development of structures reminiscent of Lafora bodies [262,263]. 
These observations prompted several groups to seek mechanisms whereby laforin could 
affect glycogen-synthesizing enzymes, more specifically, how laforin might increase 
glycogen synthase activity. One candidate is the protein kinase GSK3 which contains an 
inhibitory phosphorylation site ([109], and see above). Two groups proposed that the 
inhibitory phosphate of GSK3 can be removed by laforin [252,264], thus potentially leading 
to activation of glycogen synthase to cause the biosynthetic imbalance. Lohi et al. [252] 
suggested that laforin’s role is to detect polyglucosan appearance during glycogen synthesis 
and to initiate mechanisms to down-regulate glycogen synthase. Several studies, however, 
argue against GSK3β being a substrate for laforin [36,37,191,250,265]. Perhaps most 
convincing is the observation that the GSK3 phosphorylation state is unchanged in three 
different genetic mouse models of Lafora disease, in which the Epm2a gene is disrupted 
[36,37], dominant-negative laforin is overexpressed [265] or the Epm2b gene is disrupted 
[191]. Measurements of glycogen synthase and branching enzyme AGL activities in these 
mice also argued against the ‘branching imbalance’ hypothesis [265].
Recently, from analyses of Epm2a−/− mice, Sanz and colleagues suggested that laforin is a 
more general regulator of insulin-sensitivity and proposed that laforin is a new component of 
the insulin signalling cascade [266]. They reported that Epm2a−/− mice had enhanced 
glucose disposal, most prominently in the heart, and many insulin-dependent processes were 
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hyperactivated when compared with commercial C57BL/6 wild-type controls. GSK3β 
phosphorylation was increased, but the authors suggest that this is due to increased insulin 
signalling rather than a direct result of the inability of laforin to dephosphorylate GSK3β. In 
contrast, other experiments comparing Epm2a−/− mice with wild-type controls with a 
matched genetic background revealed no differences in glucose- or insulin-tolerance tests or 
in the insulin signalling pathway (A.A. DePaoli-Roach, D. Segvich, C. Meyer, Y. Rahimi, 
C.A. Worby, M.S. Gentry and P.J. Roach, unpublished work). A role for laforin in insulin 
signalling is thus controversial and needs further investigation.
 Laforin and autophagy
As discussed above, autophagy or an autophagy-like process is an important mechanism for 
glycogen disposal. Independent of this function, autophagy appears to be essential for 
central nervous system function as its inhibition leads to neurodegeneration, behavioural 
changes and early death in mice [267]. Autophagy is also thought to remove disease-
associated cytoplasmic aggregate-prone proteins, which stain positive with anti-ubiquitin 
antibodies and accumulate in Lafora disease, most prominently in the vicinity of Lafora 
bodies [268,269]. Consistent with this theme, Aguado et al. [270] reported that laforin 
activates autophagy by acting upstream of TSC (tuberous sclerosis complex) 2, a tumour 
suppressor mutated in patients with TSC [271]. Loss of TSC2 leads to activation of mTOR 
(mammalian target of rapamycin), which, in addition to activating protein synthesis and cell 
growth, also potently inhibits autophagy [272]. The authors concluded that laforin inhibits 
mTOR and thus activates autophagy. Therefore, when laforin is disabled, activation of 
mTOR would inhibit autophagy to cause the disease phenotype. However, the fact that 
patients with TSC do not develop Lafora bodies argues against laforin acting upstream of 
TSC2 as a mechanism for the development of Lafora bodies. Likewise, there are no reports 
of TSC-like tumours in Lafora patients or the Lafora disease mouse models. Laforin may, 
however, have multiple functions.
 Laforin as a glycogen phosphatase
A promising hypothesis in Lafora research was introduced by Dixon and colleagues [250] 
by demonstrating that laforin dephosphorylates amylopectin, the major component of plant 
starch. Amylopectin has chemistry comparable with that of glycogen (α-1,4-glycosidic 
linkages with less frequent α-1,6-branch points) and contains a significant amount of 
covalent phosphate in the form of C6- and C3-phosphomonoesters [273]. Worby et al. [250] 
also attempted to measure dephosphorylation of commercially available rabbit liver 
glycogen by laforin, but were unsuccessful, possibly because of the lack of assay sensitivity 
and/or the low phosphate content of liver glycogen. Tagliabracci et al. [37] were able to 
demonstrate that laforin could dephosphorylate rabbit muscle glycogen in vitro. Muscle 
glycogen contains approximately 10-fold more phosphate than rabbit liver glycogen [34,35]. 
Laforin released ~25% of the phosphate present in undigested rabbit muscle glycogen. 
Digestion of the glycogen with glucosidases in the presence of laforin led to release of 90% 
of the phosphate, suggesting that the majority of phosphates in the native particle are 
sterically protected from the phosphatase. Laforin activity towards glycogen is dependent on 
a functional carbohydrate-binding domain, as W32G mutant laforin was unable to bind and 
dephosphorylate glycogen, yet still retained significant activity toward PNPP [37]. The 
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hypothesis that laforin is a physiological glycogen phosphatase was strengthened by analysis 
of highly purified glycogen from laforin-knockout mice. Glycogen phosphate levels were 4–
6-fold higher in the muscle of Epm2a−/− mice compared with their wild-type counterparts 
[36,37]. Furthermore, glycogen from Epm2a−/− mice displayed a progressive deterioration in 
structure and solubility that paralleled the formation of Lafora bodies. Laforin-dependent 
hydrolysis of the phosphate in glycogen from Epm2a−/− mice largely reversed the abnormal 
appearance of the polysaccharide by electron microscopy [36]. How phosphate disturbs 
glycogen structure and chemical properties is not fully understood, but a possibility is that 
phosphate disrupts the elaborate hydrogen-bonding network associated with helical 
polyglucose [25,26].
 Malin
EPM2B (also called NHLRC1) encodes malin, a 395-residue protein that contains an N-
terminal RING finger domain followed by six NHL domains [274]. Some 56 disease-
causing mutations and several polymorphisms in the EPM2B gene have been described (The 
Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database; http://
projects.tcag.ca/lafora/). The RING finger domain is characteristic of E3 ubiquitin ligases 
[275] and Gentry et al. [253] reported that malin interacts with laforin and catalyses its 
polyubiquitylation in vitro and in cultured cells resulting in its proteasome-dependent 
degradation. As noted, laforin protein levels correlate with glycogen in a series of mouse 
models in which the muscle glycogen content was genetically manipulated. Thus, the 
increased laforin levels in patients carrying malin mutations [276] as well as Epm2b 
knockout mice [191] may be a consequence of over-accumulation of glycogen. In any event, 
if the physiological function of malin is to mediate the destruction of laforin, it is hard to 
reconcile the fact that Lafora disease is caused by recessive mutations in either the EPM2A 
or EPM2B genes. On the basis of the model of Gentry et al. [253], defective malin would 
up-regulate laforin protein levels.
Recent studies, mainly using cell culture systems, have reported that several proteins 
involved in glycogen metabolism are substrates for malin, including glycogen synthase, the 
PP1 glycogen-targeting subunit PTG, the debranching enzyme AGL and AMPK [277–280]. 
Two independent laboratories have reported that co-expression of malin and laforin resulted 
in the ubiquitylation and proteasome-dependent degradation of PTG [277,278]. They 
proposed that laforin, via its glycogen-binding domain, could recruit malin to the glycogen 
particle to promote the degradation of PTG and glycogen synthase, thereby inhibiting 
glycogen synthesis. They also suggest that neurons contain the enzymatic machinery for 
synthesizing glycogen, but do not do so because glycogen synthase is in an inactivated 
hyperphosphorylated form. Loss of laforin or malin would inhibit malin-mediated 
degradation of PTG and glycogen synthase, driving excessive glycogen accumulation by 
dephosphorylation of glycogen synthase. Interestingly, co-expression of the catalytically 
inactive form of laforin had the same effect on the degradation of PTG. However, patients 
with mutations in laforin that abolish phosphatase activity still develop Lafora bodies and 
the neurological sequalae. Perhaps the phosphatase domain is required for an independent, 
but interrelated, function. Cheng et al. [279] identified the debranching enzyme AGL as a 
substrate for malin-mediated ubiquitylation and proteasome-dependent degradation. This 
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ubiquitylation event, unlike the ones discussed above, was independent of laforin. The 
authors proposed that mutations in malin would prevent the ubiquitylation and proteasome-
dependent degradation of AGL, resulting in increased AGL protein, removal of α-1,6-
glycosidic linkages and hence polyglucosan formation. However, on the basis of the two-
stage degradation of glycogen by phosphorylase and debranching enzyme AGL, excessive 
AGL activity should only reduce branching frequency if phosphorylase, normally an 
abundant enzyme, becomes limiting. Other reports [257,281] have proposed that AMPK 
phosphorylates laforin, enhances its association with malin and thereby regulates laforin and 
malin targets. AMPK was also reported to phosphorylate the PTG phosphatase subunit and 
target it for degradation by the malin–laforin complex [282]. However, DePaoli-Roach et al. 
[191] showed that physiological activation of AMPK in muscle by exercising mice did not 
alter the levels of PTG, AGL, laforin or glycogen synthase, arguing against AMPK-mediated 
degradation of these proteins, at least on this time scale. In addition, there is a report that 
malin catalyses Lys63 ubiquitylation of the AMPK β-subunit when it is part of a trimeric 
complex in cells, a modification that would not target degradation [280]. Other studies have 
suggested that laforin and malin are recruited to aggresomes upon proteasomal inhibition 
[283]. The authors proposed that the centrosomal accumulation of malin and laforin 
enhances the ubiquitylation of malin substrates, facilitating their efficient degradation by the 
proteasome. In addition, laforin and malin were shown to form a functional complex with 
HSP70 (heat-shock protein 70) to suppress the cellular toxicity of misfolded proteins by 
promoting their degradation through the unfolded protein response [284].
Analysis of Epm2b−/− mice challenges a number of the proposed mechanisms of action of 
malin, since one would expect that loss of the E3 ubiquitin ligase would result in increased 
protein levels of the physiological substrates [191]. At 3 months of age, AGL and PTG 
levels were unchanged, as was the glycogen synthase activity ratio, arguing against AGL and 
PTG being substrates for malin-mediated degradation. Laforin protein, however, was 
significantly increased, especially in brain, and was redistributed from a soluble to an 
insoluble fraction [191]. This finding could be consistent with laforin being a malin target. 
The other interpretation is that increased insoluble glycogen sequesters the laforin, 
protecting it from degradation. Extensive analysis of glycogen-metabolizing enzymes in 
these mice failed to reveal any significant alterations, despite the fact that Lafora bodies 
were present in neurons, skeletal muscle and heart. Turnbull et al. [285] reported a 1.5-fold 
increase in skeletal muscle and liver glycogen phosphate levels in 6-month-old mice from an 
independently generated Epm2b−/− mouse model. These results suggest that malin regulates 
laforin activity and/or distribution, leading to the hyperphosphorylation of glycogen and 
subsequent formation of polyglucosan seen in Lafora patients.
 Lafora bodies and Lafora disease
There has been some debate as to whether Lafora bodies are the cause or the consequence of 
Lafora disease [240]. One argument stems from the observation that laforin-knockout mice, 
at least in one study, develop neuronal degeneration before Lafora body formation, both of 
which precede behavioural dysfunctions [286]. However, the recent generation of a double-
knockout mouse model lacking both laforin and PTG makes a strong case that glycogen, and 
Lafora bodies in particular, is linked to the neuropathology [287]. Ppp1r3c−/− mice have a 
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30% reduction in muscle glycogen, correlated with decreased glycogen synthase activation 
state and no change in phosphorylase [155]. Brain glycogen is reduced by 75%. As noted 
above, in older Epm2a−/− mice, glycogen overaccumulates. In the study of Turnbull et al. 
[287], total glycogen was elevated 4–5-fold in brain and muscle of 12-month-old Epm2a−/− 
mice. This correlated with massive increases in the number of Lafora bodies observed 
histochemically and with severe neurological symptoms. In the Epm2a−/− Ppp1r3c−/− 
double-knockout mice, glycogen and Lafora body abundance were dramatically decreased 
and the neurological defects of Epm2a−/− mice were resolved. Very recently, the presence of 
a genetic variant of PTG that decreased glycogen levels was associated with a slower 
progression of Lafora disease [288]. By epistasis, laforin is therefore upstream of PTG with 
regard to Lafora body formation. The simplest explanation is that reduced capacity to 
synthesize glycogen due to defects in PTG is sufficient to suppress polyglucosan formation. 
However, other roles for PTG cannot be excluded.
 Current status of Lafora research
The molecular era of Lafora research began in 1998. In only a dozen years or so, a vibrant 
research enterprise has emerged around what is a very rare disease. The primary focus of 
most work has been to understand the functions of the products of the two major causative 
genes, laforin and malin, and how their impairment could explain the disease process. The 
results in this young research area, as one might expect, provide numerous hypotheses 
(Figure 14), some inconsistent results and much healthy debate. The study of the Epm2a−/− 
Ppp1r3c−/− mice would appear to make a strong case that Lafora disease is indeed a 
glycogen storage disease [287]. The evidence in our view supports the idea that laforin 
evolved as an in vivo glycogen phosphatase, removing C2- and C3-phosphomonoesters from 
glycogen, and associating with glycogen via its CBM20 domain. The properties of 
hyperphosphorylated glycogen in Epm2a−/− mice match the reduced solubility of 
polyglucosans. Considering also the observation of increased glycogen phosphorylation in 
Epm2b−/− mice, we propose that glycogen phosphorylation is a central causative factor in 
Lafora disease and that laforin functions in a repair or damage-control mechanism, to 
remove the rare phosphate introduced into glycogen by glycogen synthase. Such a function 
for laforin can also explain why the onset of symptoms in Lafora patients is not immediately 
at birth. Even without functional laforin, glycogen particles can undergo normal cycles of 
degradation and resynthesis, and it is not until the phosphate exceeds a threshold that the 
glycogen structure in some particles is disturbed and destined to become a Lafora body. 
Unresolved is whether laforin has other substrates or functions in vivo. Besides the obvious 
genetic link between laforin and malin, direct physical interaction between the two proteins 
has been suggested by several studies so that defects in laforin might also have an impact on 
malin function. This may help to explain some of the other roles proposed for laforin.
What is the status of the imbalance theory? In young Epm2a−/− mice, there are no great 
changes in glycogen synthase and branching enzyme [36,265]. In old Epm2a−/− mice, there 
is a hyperaccumulation of glycogen synthase, sequestered with polyglucosan, but its activity 
is not correspondingly increased. Therefore there is little supporting evidence for the theory 
at this time. What is definitely unclear is the relationship between glycogen phosphorylation 
and its acquisition of a sparsely branched structure. In the absence of laforin, does 
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phosphorylation precede the diminished branching or do they both progress simultaneously? 
Is there any mechanistic relationship, with phosphate blocking branching enzyme action or 
being a normal part of the branching process, for example? Is there an unappreciated control 
of branching enzyme?
Perhaps the biggest unknown is the function of malin. As noted, there is no shortage of 
proposed targets (Figure 14), based mainly on experiments with cells. The levels of several 
of these protein targets are unchanged in tissue from Epm2b−/− mice making it hard to 
reconcile with the idea that the E3 ubiquitin ligase activity of malin targets these proteins for 
degradation. Perhaps the ubiquitylation has a different role. Perhaps the physiologically 
critical target for malin has yet to be discovered. Or, like laforin, perhaps malin has functions 
not obvious from its primary structure. An area that will probably receive more attention in 
the future is the possible connection between Lafora disease and autophagy, whether 
generalized macroautophagy or a more specialized process specific to glycogen, i.e. 
glycophagy. If lysosomal disposal is a means to eliminate damaged glycogen, for example 
excessively phosphorylated glycogen, malin or a malin–laforin complex might play a role in 
that process.
 CONCLUSIONS
After 150 years, one might have imagined that there would not be much more to learn about 
glycogen and its metabolism. Indeed, we now know much about the biochemistry, molecular 
biology and genetics, we have considerable molecular insight into the structure and 
mechanisms of the metabolic enzymes, and we have gained significant understanding of the 
control of glycogen metabolism in relation to nutritional status. Knowledge of the signalling 
pathways is still incomplete, however, especially with regard to muscle contraction and the 
role of AMPK. And there have been some unexpected new findings. The introduction of 
phosphate into glycogen as an error in glycogen synthase action underlies a possible link to 
Lafora disease, and leads to discussion of a totally new aspect of glycogen metabolism, 
namely that of its covalent phosphate and the role of the laforin phosphatase. The function of 
the other Lafora disease gene, which encodes malin, is a major unresolved question. 
Lysosomal disposal of glycogen, long recognized in relation to Pompe disease, is now being 
revisited to elucidate the molecular mechanism of the transport of glycogen to lysosomes. 
Other spatial aspects of glycogen metabolism, again first described many years ago, are 
beginning to be examined with modern methods for imaging subcellular localizations. The 
glycogen particle may be a prime example of a metabolic machine, accepting substrates and 
releasing products in response to signals from the cell, but still functioning autonomously 
wherever it is built.
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 Abbreviations
AGL amylo-α-1,6-glucosidase, 4-α-glucanotransferase
AICAR 5-amino-4-imidazolecarboxamide riboside
AMPK AMP-activated protein kinase
CBM20 carbohydrate-binding module 20
GAA acid α-glucosidase
GABARAP γ-aminobutyric acid type A receptor-associated protein
GABARAPL1GABARAP-like 1
GKRP glucokinase regulatory protein
GLUT glucose transporter
GSK3 glycogen synthase kinase 3
LC3 light chain 3
LGSKO liver-specific glycogen synthase-knockout
MCA Metabolic Control Analysis
MGSKO muscle-specific glycogen synthase-knockout
mTOR mammalian target of rapamycin
PAS periodic acid–Schiff
PKA protein kinase A
PKB protein kinase B
PNPP p-nitrophenyl phosphate
PP protein phosphatase
PRKAG2 AMPK γ2 non-catalytic subunit
PSSM polysaccharide storage myopathy
PTG protein targeting to glycogen
Stbd1 starch-binding domain protein 1
TCA trichloroacetic acid
TSC tuberous sclerosis complex
UGPPase UDP-glucose pyrophosphatase
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Figure 1. Glycogen structure
(A) Polymerizing α-1,4-glycosidic linkages and a branching α-1,6-glycosidic linkage are 
shown. (B) The tiered model for glycogen organization in which inner B-chains on average 
carry two branches and the outer A-chains are unbranched. The black circle denotes 
glycogenin.
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Figure 2. Glycogen particles
Shown are the well-established glycogen-associated proteins: the metabolic enzymes 
(mauve) glycogenin (GN), glycogen synthase (GS), phosphorylase (PH) and debranching 
enzyme (DBE); the protein kinases (red) phosphorylase kinase (PH kinase) and AMPK; the 
phosphatases (green) type 1 catalytic subunit (PP1c) and laforin (LF); the PP1 glycogen-
targeting subunits (blue) RGL, GL and PTG; and the putative membrane-anchoring protein 
Stbd1. Malin has been suggested to bind glycogen via interaction with laforin. 
Phosphorylase kinase, Stbd1 and RGL bind membranes. Numerous protein–protein 
interactions are either known or proposed to exist among these glycogen-binding proteins.
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Figure 3. Overview of glycogen metabolism
Glcout, extracellular glucose; Glcin, intracellular glucose; HK, hexokinase; G6Pase, 
glucose-6-phosphatase; PGM, phosphoglucomutase; UP, UDP-glucose pyrophosphorylase; 
UGPPase, UDP-glucose pyrophosphatase; GN, glycogenin; GS, glycogen synthase; BE, 
branching enzyme; PH, glycogen phosphorylase; DBE, debranching enzyme; GAA, 
lysosomal α-glucosidase; GNG, gluconeogenesis.
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Figure 4. Structure of mammalian glycogenin
(A) Ribbons representation of the glycogenin dimer. The active sites are denoted by the 
bound substrate UDP-glucose (magenta). The location of Tyr195 near the dimer interface is 
indicated using magenta colouring of the residue. (B) The active site of glycogenin. 
Residues discussed in the text are labelled, and the position of the catalytically essential 
Mn2+ ion is shown using a purple sphere.
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Figure 5. Regulatory features of glycogen synthase
Shown is a comparison of the general architecture of yeast and mammalian glycogen 
synthases in terms of phosphorylation sites (light blue, not to scale) and the arginine-rich 
cluster implicated in conferring sensitivity to activation by glucose 6-phosphate (green). The 
conserved arginine residues and the phosphorylated residues are in black and marked by 
dots. Some of the protein kinases involved in phosphorylating the mammalian enzyme are 
linked to sites they modify. See the legend to Table 2.
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Figure 6. Ribbons diagram of eukaryotic glycogen synthase
The diagram highlights the sequence insertions and deletions of glycogen synthase that 
confer its allosteric regulation and preference for UDP-glucose. The secondary-structural 
elements conferring its tetrameric arrangement are coloured magenta. The location of the 
ten-residue deletion relative to the bacterial enzymes that conveys glucose 6-phosphate 
regulation is coloured blue. The inserted loop of residues that confer preference for UDP-
glucose is coloured green.
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Figure 7. Glucose 6-phosphate activation
The active sites of glycogen synthase are occluded in the absence of glucose 6-phosphate 
(A), but are opened and freed for glycogen access in the activated state (B). Glucose 6-
phosphate is bound at the interface between subunits with multiple charged residues 
interacting with the phosphate moiety and relatively few contacts with the glucose moiety 
(C).
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Figure 8. Interactions at the regulatory interface in different conformational states of yeast 
glycogen synthase
(A) The binding of glucose 6-phosphate reorganizes the interface and positions the 
regulatory helices approximately 12Å apart. (B) One of the basal state conformations of 
yeast glycogen synthase where two sulfate molecules are bound next to Arg589 on the 
opposite face of the regulatory helix from where glucose 6-phosphate is bound. The 
regulatory helices are positioned approximately 8 Å apart in this conformation. (C) Another 
conformational state observed for glycogen synthase when a single sulfate molecule is 
bound between the regulatory helices and pulls the helices to within approximately 5 Å of 
one another. This state may resemble the inhibited phosphorylated state.
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Figure 9. Maltodextran binding in glycogen phosphophorylase and glycogen synthases
(A) A ribbons representation of phosphorylase with a maltodextran bound in the ‘glycogen 
storage site’. (B) A ribbons representation of the glycogen synthase monomer from E. coli 
displaying maltodextran-binding sites ‘c’ and ‘d’ that are located on its N-terminal domain. 
(C) A ribbons representation of a single subunit in yeast glycogen synthase displaying the 
maltodextran bound to site-1 located in the N-terminal domain. (D) A ribbons representation 
of a single subunit of yeast glycogen synthase displaying the locations of all four 
maltodextran-binding sites.
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Figure 10. Active site of yeast glycogen synthase
Those residues in Gys2p responsible for recognizing and binding the donor nucleotide sugar 
substrate are labelled. The glutamate residues present in the EX7E motif probably participate 
in glucosyl transfer from the donor to acceptor substrate (Glu509) and in positioning the 
uridine ribose moiety (Glu517).
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Figure 11. Possible mechanism for glycogen phosphorylation
The usual glycogen synthase reaction is shown on the left where glucose from UDP-glucose 
is added to the non-reducing end to form a new α-1,4-glycosidic linkage. The proposed 
mechanism for the introduction of phosphate would involve the formation of either 
glucose-1,2-cyclic phosphate (a) or glucose-1,3-cyclic phosphate (b) in the enzyme active 
site. Reaction of C-1 of the cyclic phosphate would lead to addition of either a glucose 2-
phosphate or a glucose 3-phosphate to the non-reducing end.
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Figure 12. Control of glycogen synthesis in muscle
Both insulin and exercise increase glucose uptake via GLUT4. Increased glucose 6-
phosphate (Glc-6-P) levels provide feedforward activation of GS (glycogen synthase). 
Insulin also causes dephosphorylation and activation of glycogen synthase by promoting the 
inactivation of GSK3 by Akt. The effect of exercise on glycogen synthase phosphorylation is 
more complex, potentially dephosphorylating via a PP1G containing RGL and well as 
increasing phosphorylation via activation of protein kinases such as AMPK. PhK, 
phosphorylase kinase.
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Figure 13. Degradation of glycogen
Glycogen is converted into glucose (Glc) by two pathways: (a) the classic cytosolic pathway 
controlled by cAMP and PKA, and mediated by glycogen phosphorylase (PH) and 
debranching enzyme (DBE); and (b) the lysosomal pathway in which degradation is 
ultimately catalysed by the lysosomal GAA. The latter pathway is poorly understood 
mechanistically, but probably resembles autophagy. It may be an example of selective 
autophagy with cargo specificity conferred by Stbd1 which would anchor glycogen to 
membranes and interact with the ATG8 family member GABARAPL1. The model also 
depicts the possibility that abnormally phosphorylated and/or branched glycogen is 
preferentially disposed of by this pathway. GS, glycogen synthase; LF, laforin.
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Figure 14. Reported interactions among laforin, malin and glycogen-metabolizing proteins
The Figure summarizes some of the interactions reported for laforin and malin, as discussed 
in the text, based on studies in vitro, in cell systems and genetically modified mice. Blue 
single-headed arrows depict an enzyme–substrate relationship. Red double-headed arrows 
indicate a protein–protein interaction. Dashed green arrows indicate signalling pathways. 
Asterisks indicate some instances where analyses of Epm2a −/− and/or Epm2b −/− mice do 
not seem consistent with the proposed interaction. LF, laforin; LB; Lafora bodies; GS, 
glycogen synthase; DBE, debranching enzyme.
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Table 1
Glucose and phosphate distribution within a glycogen particle
Tier* Glucose/tier† Chains/tier‡ Total glucose§ Phosphate/tier‖
1 13 1 13 0.03
2 26 3 39 0.08
3 52 7 91 0.2
4 104 15 195 0.4
5 208 31 403 0.8
6 416 63 819 1.6
7 832 127 1651 3.3
8 1664 255 3315 7
9 3328 511 6643 13
10 6656 1023 13299 27
11 13312 2047 26611 53
12 26624 4095 53235 106
*
Based on the model of Figure 1.
†
Based on a chain length of 13.
‡Number of chains per tier; chains(tier n) = 2n − 1
§Sum of the number of glucose residues up to and including this tier.
‖Covalent phosphates, assuming one phosphate per 500 glucose residues and an even distribution of phosphates between the inner and outer tiers. 
Total phosphates in a 12-tier molecule on this model would be ~212.
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Table 2
Muscle glycogen synthase phosphorylation sites
CAMKII, Ca2+/calmodulin-dependent protein kinase II; CK1, protein kinase casein kinase 1; CK2, protein 
kinase CK2; DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase; PASK, PAS (Per/Arnt/
Sim) domain-containing protein kinase; PhK, phosphorylase kinase; PKC, protein kinase C.
Phosphorylation site
Common designation* Residue (rabbit)† Residue (mouse)† In vitro kinase(s)
Site 2 7 8 AMPK, CAMKII, PhK, PKA, PKC
Site 2a 10 11 CK1
Site 3a 640 641 GSK3, PASK, DYRK
Site 3b 644 645 GSK3, p38β
Site 3c 648 649 GSK3
Site 4 652 653 GSK3
Site 5 656 657 CK2
Site 1a 697 698 PKA, PKC
Site 1b 710 711 PKA, CAMKII
*Site designations made before the protein sequence was known, but still used in many publications.
†
Residue numbers were first derived from biochemical studies of rabbit muscle enzyme. More recent studies of mouse (and human) glycogen 
synthase generally follow HUGO recommendations that begin with the translational start site and thus differ by one. Both usages are present in the 
literature.
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